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Introduction
In the context of limited resources, evidence on costs and 
cost-effectiveness of alternative methods of delivering 
health-care services is increasingly important to facilitate 
appropriate resource allocation decisions. Care at the end 
of life is known to account for a large proportion of health-
care resources. Estimates from the United States indicate 
that 25% of health-care expenditure is related to patients in 
their last year of life.1 In the United Kingdom, it is esti-
mated that approximately 20% of hospital bed days are 
taken up by end-of-life care.2 Palliative care services have 
been expanding worldwide with the aim of improving the 
experience of patients with terminal illness at the end of life 
through better symptom control, coordination of care and 
improved communication between professionals and the 
patient and family.3,4
However, the application of economic evaluation to 
palliative care has been slow to develop, and the evidence 
base remains small. While available studies indicate that 
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palliative care is cost-saving, the results should be treated 
with caution (e.g. heterogeneous methods, poor quality of 
evaluation5). There are challenges in applying standard 
economic evaluation techniques to palliative care, some of 
which relate to difficulties in capturing all relevant data 
(e.g. informal care costs), while others refer to conceptual 
issues of valuing benefits. There are concerns that the full 
impacts of the interventions are not being captured. For 
example, the appropriateness of applying standard eco-
nomic evaluation techniques (e.g. the Quality Adjusted 
Life Year (QALY)) to measuring outcomes in palliative 
care has been questioned.5 The duration of effect is inevi-
tably limited in many palliative interventions, but a short 
good experience may be given a high value and this is not 
captured in the standard approach of adding up QALYs.4,6
Thus, there are reasons why studies in this area do not 
undertake formal cost-effectiveness analyses, but rather 
assess implications of palliative care interventions on costs 
separately from outcomes. As a result, methodological 
approaches are varied and often rely on relatively small 
observational studies.3 It is important to keep these chal-
lenges in mind when reviewing economic studies in this 
field, looking for consistent patterns across study results 
rather than undertaking formal meta-analyses. Existing sys-
tematic reviews have assessed some of the evidence on 
costs and cost-effectiveness of palliative care,3,4,7 but the 
focus and the extent to which the quality of the cost analy-
ses is assessed has varied.
This article presents results from a comprehensive lit-
erature review of available international evidence on the 
costs and cost-effectiveness of palliative care interven-
tions in any setting (e.g. hospital-based, home-based (see 
the ‘Methods’ section for discussion of terminology)) 
over the period 2002–2011. Given the linkages between 
health-care utilisation and costs, evidence on service utili-
sation is also assessed. While we follow standard methods 
for conducting a systematic review and assess the quality 
of the evidence against a set of criteria drawn from the 
evaluation literature, we take a deliberately inclusive 
approach and no study is omitted from the summary find-
ings on the basis of poor quality. This reflects our focus on 
identifying consistent patterns in results within a small 
field of evidence.
The ‘Methods’ section outlines the research question for 
the review and presents the methods. Quality assessment and 
key findings of the included studies are presented and dis-
cussed in the ‘Results for literature review (2002–2011)’ sec-
tion, while the ‘Conclusion’ section concludes the article.
Methods
Terminology and objectives
The terms ‘palliative’ and ‘hospice’ have not been used 
consistently in the literature. Given the aim to capture a 
comprehensive review of studies in this area, this review 
avoids making strict delineations between hospice and pal-
liative care. In outlining key findings, we adopt the same 
terminology as applied in the source literature. The general 
term ‘palliative care intervention’ used in this article is 
intended to cover interventions that specify a palliative care 
focus and/or hospice-related care. The term ‘end-of-life’ 
was kept deliberately vague so as to include as many stud-
ies as possible, for example, studies that focus on the last 7 
days, last month, last 3 months and so on.
The specific objectives of the review were to
•	 Identify studies that investigate the cost or resource 
use implications of a ‘palliative care intervention’ 
relative to some type of comparator or control.
•	 Identify studies that investigate the cost-effective-
ness of a ‘palliative care intervention’ relative to 
some type of comparator or control.
Search strategy
Key bibliographic and review databases were searched 
including PubMed (including MEDLINE), EURONHEED, 
the Applied Social Sciences Index (ASSIA) and the 
Cochrane library of databases (including the National 
Health Service Economic Evaluation Database, the 
Database of Systematic Reviews, the Health Technology 
Assessment Database and others).
The search strategy was initially limited to articles writ-
ten in the English language, published in the period 1980–
2011 and involving human subjects. The search was kept as 
broad as possible as there can be quite a lot of overlap 
between the palliative care and ‘end-of-life’ literatures. The 
strategy employed a list of terms grouped under three main 
headings intended to identify all publications relevant to 
the review question: life stage (e.g. end of life, last year of 
life, life-threatening and so on) OR type/location of care 
(e.g. palliative, hospice and so on) AND costs/cost-effec-
tiveness (e.g. cost, economic, price and so on). The full list 
of search terms is available on request from the authors.
Applying these search criteria to the databases provided 
a list for title screening. Titles were excluded on the basis of 
six criteria: an exclusively non-Western focus, a pharmaco-
logical focus, editorials or other descriptive (e.g. historical 
discussion), literature reviews (systematic or otherwise), no 
specific focus on palliative or hospice care, or no specific 
focus on costs or health-care utilisation. Any citations that 
were ambiguous with regard to the exclusion criteria were 
retained for the next stage. Duplicates were identified and 
removed. Abstracts from the retained titles were reviewed 
and included for full text review unless any of the above 
exclusion criteria applied. If there were any ambiguity fol-
lowing the abstract review, the article moved to the next 
stage. The full text for those articles found to be potentially 
relevant from the abstract screening were reviewed in 
detail. Only those that met the criteria of examining the cost 
and/or utilisation implications of a palliative care interven-
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tion with some form of comparator were included in the 
final literature review. References of the retrieved articles 
were also hand-searched for further relevant studies. Data 
were extracted (onto an MS Access database) from the 
selected papers to record key study characteristics and to 
facilitate quality assessment.
Quality assessment
There is no single approach to assessing quality for a sys-
tematic review, and different elements of quality need to be 
considered for different study designs.8,9 For the purpose of 
this review, it was difficult to find an existing single set of 
criteria that could be applied given the diversity in the types 
of studies included and given the specific focus on cost 
analysis. Thus, this review compiled a set of 31 indicators 
suitable for evaluating a diverse set of papers, drawing on 
existing evaluation criteria (see Table 1).4,8,10–13 As a gen-
eral guide, quality assessment of any study should consider 
risk of bias, statistical issues, quality of reporting and gen-
eralisability.9 These factors informed the selection of indi-
cators.
The 31 indicators cover six core issues:
1. Study description (e.g. details on objectives, impor-
tance of the research question outlined, clear 
description of the alternatives being compared)
2. Sample selection and size (e.g. details on how the 
sample was selected, adequate sample size)
3. Measurement (e.g. clear description of outcome 
measures, viewpoint of analysis clearly stated)
4. Reporting (e.g. details on baseline demographic and 
outcome measures, details of currency and adjust-
ments for inflation)
5. Analysis (e.g. clear description of statistical ana-
lytic methods, adequate controls for variations in 
individual characteristics and self-selection and 
other sources of bias)
6. Conclusions (e.g. statements of study limitations)
The quality of the papers was judged by a panel of three 
reviewers to ensure consistency. The reviewers discussed 
and agreed on a final mark for each indicator. Each indicator 
was allocated one of three possible marks: 0 (poor), 2 
(incomplete or not clear) or 4 (good). In some cases, the indi-
cator was not applicable for the paper and was marked as 
such. An overall mark, ranging from 0 (lowest quality) to 1 
(highest quality), was then calculated for each of the six core 
issues (i.e. study description, sample selection and size, 
measurement and so on). For example, ‘study description’ 
covers three indicators. If a particular paper scored 4, 2 and 0 
for indicators one, two and three respectively, the numerator 
for ‘study description’ would be 6 and the denominator 
would be 12 (4 being the maximum mark for each indicator), 
giving an overall score of 0.5. Where a particular indicator 
was not applicable, it was excluded from the calculation.
However, while quality scales and summary scores have 
been used in a number of palliative care reviews,3,4 it is 
important to note that their limitations and their use in gen-
eral have been questioned.9 As shown in the ‘Results for 
literature review (2002–2011)’ section, an overall score for 
each paper can be useful to classify papers into broad qual-
ity groupings, but this is more informative when combined 
with other factors, such as an assessment of the type of ana-
lytical methods employed by each paper. As in other litera-
ture reviews of palliative care,3,4 it was not possible to 
undertake formal meta-analysis of the cost findings, given 
the heterogeneity of the methods in the studies included in 
this review. As an alternative, the study findings are dis-
cussed broadly in order of general assessment of quality, 
drawing on the formal assessment ratings and also taking 
into account the sophistication of the statistical analysis 
undertaken.
Results for literature review (2002–
2011)
Study selection
A total of 54,268 papers were returned from the initial bib-
liographic and review database search (Figure 1). Following 
the title screening, 53,041 papers were omitted as they 
clearly met the exclusion criteria. Of the 1227 papers that 
moved on to the abstract screening stage, 100 duplicates 
were omitted and 640 met the exclusion criteria. The full 
texts of the remaining 487 papers were retrieved. Focusing 
on the period 2002–2011, 285 papers were reviewed for 
potential inclusion in the literature review, of which 46 
papers met the criteria of examining the cost and/or utilisa-
tion implications of a palliative care intervention with some 
form of comparator.
Study characteristics
Table 2 outlines the key characteristics of the 46 papers 
selected for inclusion in the review. Drawing on classifica-
tions outlined in the literature,9 the papers fall into six main 
categories. There are 5 randomised controlled trials (RCTs), 
2 non-RCTs, 34 cohort studies, 2 case studies, 2 before-
and-after studies and 1 ‘other’ study.
The included papers cover a range of different palliative 
care interventions including hospice care, hospital-based 
palliative care programmes, home-based palliative care 
programmes and others. As noted earlier, the definitions of 
palliative care interventions vary across studies, and in a 
number of cases, adequate descriptions of the intervention 
being studied were relatively limited, making international 
comparisons more difficult. Most of the papers analysed 
the impact of one specific palliative care intervention rela-
tive to a control, while three focused on comparisons across 
different types of palliative care or on palliative care in dif-
ferent locations.
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Table 1. Quality indicators criteria.
No. Indicator Applicable to Comparator groups No comparator groups
(A) Study description
 1.
 
 
Specific objectives All 4: It is clear what the research question is
2: The research question is not clearly stated
0: The research question is not stated at all
 2.
 
 
The importance of the 
research question is stated
All 4: Justification/rationale is provided for the focus of the study
2: Not clear what the rationale behind the specific research question is
0: No introduction justification/rationale is provided
 3.
 
 
 
The alternatives being 
compared are clearly 
described
All 4: Each alternative is clearly described 4: The programme or intervention 
is clearly described
2: Only one alternative is described 
(and the other not at all), or only one 
is clearly described (and the other only 
vaguely), or none of the alternatives are 
clearly described (all only vaguely)
2: The programme or intervention 
is not clearly described
0: The alternatives are not described 
at all
0: The programme or intervention 
is not described at all
(B) Sample selection and size
 4.
 
 
Clear description of 
inclusion and exclusion 
criteria
All 4: The inclusion and exclusion criteria are clearly described
2: The inclusion/exclusion criteria are not clearly described
0: The inclusion/exclusion criteria are not described at all
 5.
 
 
Comprehensive strategy for 
identification of potential 
cases
All 4: The study has taken a comprehensive approach to identifying all potential 
participants for the study
2: It is not clear whether a comprehensive approach has been taken, or the 
approach could be more comprehensive
0: A comprehensive approach has not been taken
 6.
 
 
 
Patient recruitment rate > 
70%
Prospective 4: Of all potential patients to be recruited to the study, more than 70% have 
been recruited
2: The recruitment rate is not clear
0: The recruitment rate is lower than 70%
Not appropriate: retrospective study
 7.
 
 
 
Evaluation of non-
participants to judge 
generalisability
All 4: Patients excluded from analysis are evaluated
2: It is not clear whether patients excluded from analysis have been evaluated, 
or only limited evaluation has been undertaken
0: Evaluation of patients excluded from analysis is not reported
Not appropriate: if there are no exclusions
 8.
 
 
 
How sample size was 
determined
Prospective 4: Is the method for calculating sample size reported
2: The method for calculating sample size is not clear
0: The method for calculating sample size is not reported
Not appropriate: retrospective study
 9.
 
 
Adequate sample size for 
each comparator group
All 4: Sample size for each comparator 
group ≥ 30
4: Sample size ≥ 30
2: Sample size for each comparator 
group not clear
2: Sample size not clear
0: Sample size for one/more 
comparator groups < 30
0: Sample size < 30
(C) Measurement
10.
 
 
Clearly defined primary 
and secondary outcome 
measure(s)
All 4: All specified outcome measures are clearly described
2: The description of one/more outcome measures is not clear; the 
descriptions for some outcomes are clear but not clear/not included for 
others
0: None of the specified outcome measures are described
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No. Indicator Applicable to Comparator groups No comparator groups
11.
 
 
Use of validated subjective 
outcome measures
All 4: Measurement of subjective outcomes is undertaken using recognised, 
validated measures
2: Measures used for subjective outcomes are not clear; recognised validated 
measures are used for some but not all of the subjective outcomes
0: None of the subjective outcomes are measured using recognised, validated 
measures
12.
 
 
The viewpoint(s) of the 
analysis are clearly stated
Cost 4: The perspective for the cost analysis is clear
2: The perspective for the cost analysis is not clear
0: The perspective for the cost analysis not stated at all
13.
 
 
 
Quantities of resources are 
reported
All 4: Quantities of resource use clearly presented
2: Quantities of resource use presented but not clearly
0: Quantities of resource use not presented
Not appropriate: quantities of resource use not collected in the study
14.
 
 
 
Unit costs are reported Cost 4: Unit costs are clearly presented
2: Unit costs are presented but not clearly or not for all relevant costs
0: Unit costs are collected but not presented
Not appropriate: unit costs are not collected in the study
15.
 
 
Methods for the estimation 
of quantities and unit costs 
are described
All 4: Methods for calculating resource use and/or costs are described
2: Methods for calculating resource use and/or costs are not clearly described 
or are only described from some
0: Methods for calculating resource use and/or costs are not described for any
16.
 
 
Time horizon of costs and 
benefits is stated
All 4: It is clear what time period the data refer to
2: It is not clear what time period the data refer to
0: No reference at all to the time period
(D) Reporting
17.
 
 
Baseline demographics and 
clinical characteristics of 
each group
All 4: Demographic and clinical 
characteristics are reported for each 
comparison group
4: Demographic and clinical 
characteristics are reported for 
the study group
2: Demographic and clinical 
characteristics are reported for only 
one group, not clearly presented
2: Demographic and clinical 
characteristics are incomplete/not 
clearly presented
0: Demographic and clinical 
characteristics are not presented
0: Demographic and clinical 
characteristics are not presented
18.
 
 
Baseline outcome measures 
of each group prior to the 
intervention
All 4: Outcome measures at baseline, prior 
to intervention, are reported for each 
comparison group
4: Outcome measures at baseline, 
prior to intervention, are reported 
for the study group
2: Outcome measures at baseline, prior 
to intervention, are reported for one 
group only, or not clearly presented for 
one/either group
2: Outcome measures at baseline, 
prior to intervention, are not 
clearly presented for the study 
group
0: Outcome measures at baseline, prior 
to intervention, are not reported
0: Outcome measures at baseline, 
prior to intervention, are not 
reported
19.
 
 
No significant differences 
present across study groups
All 4: There are no statistically significant 
differences in demographic or clinical 
characteristics among the comparison 
groups in the study
Not appropriate
 
 
2: It is not clear whether there are 
statistically significant differences in 
demographic or clinical characteristics 
among the comparison groups in the study
0: There are statistically significant 
differences in demographic or clinical 
characteristics among the comparison 
groups in the study
(Continued)
Table 1. (Continued)
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No. Indicator Applicable to Comparator groups No comparator groups
20.
 
 
Currency and price date are 
recorded
Cost 4: Both currency and price date are specifically reported
2: Only one of currency or price date are specifically reported
0: Neither currency nor price date are specifically reported
21.
 
 
Details of currency of price 
adjustments for inflation or 
currency conversion are 
given
Cost 4: Details of adjustments for inflation or currency conversion are clearly 
presented, or the currency and price date are indicated and the data were 
collected within one calendar year
2: Details on adjustments for inflation/currency are not clear
0: No details are given on adjustments for inflation/currency
(E) Analysis
22.
 
 
 
Details of any statistical 
methods used are given 
(univariate)
All 4: Statistical methods for univariate analysis are reported
2: Statistical methods are not clear
0: Statistical methods not reported
Not appropriate: univariate analysis not undertaken
23.
 
 
 
For each primary and 
secondary outcome, a 
summary of results for each 
group and estimated effect 
size and precision
All 4: For each outcome, results from univariate analysis are presented for each 
comparison group, including effect size and precision
2: Presentation of results of univariate analysis is unclear
0: Results from univariate analysis not presented
Not appropriate: univariate analysis not undertaken
24.
 
 
 
Details of any model used 
are given (multivariate)
All 4: Details of any regression analysis are reported
2: Regression analysis is not clear
0: Regression analysis is not reported
Not appropriate: multivariate analysis not undertaken
25.
 
 
 
The choice of model used is 
appropriate
All 4: The model is appropriate for the dependent variable, the full list of 
covariates is included
2: The model is appropriate for the dependent variable but the full list of 
covariates is not included, or it is not clear what model has been used
0: The model is not appropriate for the dependent variable
Not appropriate: multivariate analysis not undertaken
26.
 
 
 
A summary of results 
for each model including 
coefficients/odds ratios/
marginal effects and 
precision
All 4: The regression results are clearly presented for each model including 
coefficients/odds ratios/marginal effects and precision
2: The regression results are incomplete, or are not clearly presented
0: The regression results are not presented
Not appropriate: multivariate analysis not undertaken
27.
 
 
The statistical methods/
model adequately control 
for variation across the 
comparison groups
All 4: The type of statistical analysis 
undertaken controlled well for variation 
across the groups when comparing the 
outcomes of interest
Not appropriate
 
 
2: The details of the statistical analyses 
are unclear so it is not clear whether 
there was sufficient control of variation 
across the groups
0: More statistical analysis could 
have been undertaken to control for 
variation across the groups
(F) Conclusions
28.
 
 
 
Major outcomes are 
presented in a disaggregated 
as well as aggregated form
All 4: Details of major outcomes presented for itemised costs/services as well as 
aggregated values
2: Unclear presentation of major outcomes
0: Only aggregated values presented
Not appropriate: only aggregated values estimated
29.
 
 
The answer to the study 
question is given
All 4: The discussion or conclusions refer to the initial study objectives and 
outline the answers
2: It is not clear that the analysis has directly addressed the study question
0: No summary statements included
Table 1. (Continued)
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30.
 
 
Conclusions follow from the 
data reported
All 4: The text in results/discussion/conclusions follows the data presented
2: The text in results/discussion/conclusions does not clearly follow the data 
presented
0: No discussion of the data presented or the discussion does not 
correspond to the data presented
31.
 
 
 
 
Conclusions are 
accompanied by the 
appropriate limitations/
caveats
All 4: The study outlines key limitations 
and should refer at least to issues of 
generalisability, uncontrolled variation 
across comparison groups
4: The study outlines key 
limitations and should refer 
at least to the issue of 
generalisability
2: Some limitations are listed but 
without consideration of one of 
generalisability or uncontrolled variation
2: Some limitations are listed 
but without consideration of 
generalisability
0: No limitations are listed, or no 
reference to generalisability and 
uncontrolled variation
0: No limitations are listed
Source: Adapted from existing evaluation criteria.4,8,10–13
Table 1. (Continued)
Addional papers, retrieved full text 
(2002-2011)
n = 21
Total number of tles idenfied for tle screening (1980–2011)
n = 54,268
Total number of tles considered potenally relevant, connue to abstract screening (1980–2011)
n = 1,227
Titles excluded:
Duplicates n = 100
Abstracts excluded n = 640
PubMed
n=935
EURONHEED
n = 4
ASSIA
n = 118
Cochrane
n = 170
Abstracts excluded (1980-2001):
n = 223
Number of abstracts considered potenally
relevant, retrieved full text (2002–2011)
n = 264
Total number of abstracts considered potenally relevant, retrieved full text (1980–2011)
n = 487
Papers excluded (2002-2011):
n = 240
Number of papers included in the systemac review 
(2002–2011)
n = 46
PubMed
n = 44,961
EURONHEED
n = 715
ASSIA
n = 3,214
Cochrane
n = 5,378
Figure 1. Flow Diagram of Study Selection Process1
Additional papers include papers added from ongoing search alerts (PubMed) and references from retrieved papers.
 by guest on July 15, 2013pmj.sagepub.comDownloaded from 
8 Palliative Medicine 0(0)
Ta
bl
e 
2.
 L
ite
ra
tu
re
 r
ev
ie
w
 p
ap
er
 c
ha
ra
ct
er
is
tic
s 
(n
 =
 4
6)
.a
St
ud
y 
C
ou
nt
ry
St
ud
y 
ty
pe
Pr
og
no
si
s
N
o.
 o
f p
at
ie
nt
s
C
os
t/
ut
ili
sa
tio
n
K
ey
 r
es
ul
ts
 
In
te
rv
en
tio
n
C
on
tr
ol
Ba
ki
ta
s 
et
 a
l.1
9
U
ni
te
d 
St
at
es
R
an
do
m
is
ed
 
co
nt
ro
lle
d 
tr
ia
l
A
pp
ro
xi
m
at
el
y 
1 
ye
ar
16
1 
pa
lli
at
iv
e 
ca
re
16
1 
us
ua
l c
ar
e
U
til
is
at
io
n
N
o 
di
ffe
re
nc
es
 b
et
w
ee
n 
PC
 a
nd
 c
on
tr
ol
 g
ro
up
 in
 n
um
be
r 
of
 d
ay
s 
in
 
ho
sp
ita
l (
p 
=
 0
.1
4)
, n
um
be
r 
of
 d
ay
s 
in
 IC
U
 (
p 
>
 0
.9
9)
 o
r 
nu
m
be
r 
of
 E
D
 
vi
si
ts
 (
p 
=
 0
.5
3)
Ba
ck
 
et
 a
l.5
7
  
U
ni
te
d 
St
at
es
C
oh
or
t 
st
ud
y
≤3
 m
on
th
s
82
 h
os
pi
ta
l 
pa
lli
at
iv
e 
ca
re
 c
as
e 
m
an
ag
em
en
t
18
3 
us
ua
l 
ho
sp
ita
l-b
as
ed
 
ca
re
U
til
is
at
io
n
PC
 p
at
ie
nt
s 
en
ro
lle
d 
>
11
3 
da
ys
 le
ss
 li
ke
ly
 t
ha
n 
co
nt
ro
l t
o 
ha
ve
 a
cu
te
 
ca
re
 a
dm
is
si
on
 in
 la
st
 6
0 
da
ys
 o
f l
ife
: O
R
 =
 0
.3
06
, 9
5%
 C
I =
 0
.1
17
–0
.8
02
A
LO
S 
pe
r 
ac
ut
e 
ca
re
 a
dm
is
si
on
 s
ig
. s
ho
rt
er
 fo
r 
PC
 p
at
ie
nt
s 
re
la
tiv
e 
to
 
co
nt
ro
l (
p 
<
 0
.0
5)
R
es
ul
ts
 o
n 
nu
m
be
r 
of
 a
cu
te
 c
ar
e 
da
ys
 <
60
 d
ay
s 
of
 li
fe
 d
ep
en
de
d 
on
 t
he
 
le
ng
th
 o
f P
C
 e
nr
ol
m
en
t
Be
nd
al
y 
et
 a
l.2
8
 
U
ni
te
d 
St
at
es
C
oh
or
t 
st
ud
y
–
61
 h
os
pi
ta
l-
ba
se
d 
pa
lli
at
iv
e 
ca
re
55
 u
su
al
 
ho
sp
ita
l-b
as
ed
 
ca
re
C
os
t 
an
d 
ut
ili
sa
tio
n
PC
 c
on
su
lta
tio
n 
as
so
ci
at
ed
 w
ith
 s
ig
. l
ow
er
 h
os
pi
ta
l c
ha
rg
es
 r
el
at
iv
e 
to
 
co
nt
ro
l (
p 
<
 0
.0
01
)
N
o 
si
g. 
di
ffe
re
nc
e 
in
 A
LO
S 
du
ri
ng
 fi
na
l h
os
pi
ta
l a
dm
is
si
on
 b
et
w
ee
n 
PC
 
an
d 
co
nt
ro
l (
p 
=
 0
.6
5)
Br
um
le
y 
et
 a
l.2
0
   
U
ni
te
d 
St
at
es
N
on
-
ra
nd
om
is
ed
 
co
nt
ro
lle
d 
st
ud
y
≤1
 y
ea
r 
(In
te
rv
en
tio
n)
; 
≤2
 y
ea
rs
 
(C
on
tr
ol
)
16
1 
ho
m
e-
ba
se
d 
pa
lli
at
iv
e 
ca
re
13
9 
us
ua
l 
(M
ed
ic
ar
e 
gu
id
el
in
e)
 
ho
m
e 
ca
re
C
os
t 
an
d 
ut
ili
sa
tio
n
M
ea
n 
co
st
 o
f c
ar
e 
fo
r 
PC
 g
ro
up
 U
S$
65
80
 (
19
99
 p
ri
ce
s)
 lo
w
er
 t
ha
n 
fo
r 
co
nt
ro
l (
p 
va
lu
es
 n
ot
 r
ep
or
te
d)
Si
g. 
lo
w
er
 u
se
 o
f E
D
, a
cu
te
 in
pa
tie
nt
 s
er
vi
ce
s 
in
 P
C
 r
el
at
iv
e 
to
 c
on
tr
ol
 
gr
ou
p 
(p
 <
 0
.0
01
)
Lo
w
er
 u
se
 o
f p
hy
si
ci
an
 o
ffi
ce
 v
is
its
 (
p 
<
 0
.0
01
) 
an
d 
sk
ill
ed
 n
ur
si
ng
 
se
rv
ic
es
 (
p 
=
 0
.0
05
) 
fo
r 
PC
 v
er
su
s 
co
nt
ro
l
PC
 g
ro
up
 h
ad
 s
ig
. m
or
e 
ho
m
e 
vi
si
ts
 r
el
at
iv
e 
to
 c
on
tr
ol
 (
p 
<
 0
.0
01
)
Br
um
le
y 
et
 a
l.1
8
  
U
ni
te
d 
St
at
es
R
an
do
m
is
ed
 
co
nt
ro
lle
d 
tr
ia
l
–
14
5 
in
-h
om
e 
pa
lli
at
iv
e 
ca
re
15
2 
us
ua
l 
ho
m
e 
ca
re
C
os
t 
an
d 
ut
ili
sa
tio
n
To
ta
l c
os
ts
 U
S$
75
52
 (
20
02
 p
ri
ce
s)
 lo
w
er
 fo
r 
PC
 g
ro
up
 o
ve
r 
st
ud
y 
pe
ri
od
: 9
5%
 C
I =
 −
U
S$
12
,7
30
 t
o 
−
U
S$
23
74
, t
 =
 −
3.
63
, p
 <
 0
.0
01
A
ve
ra
ge
 c
os
t 
of
 c
ar
e 
pe
r 
da
y 
U
S$
95
.3
0 
fo
r 
PC
 g
ro
up
 c
om
pa
re
d 
w
ith
 
U
S$
21
2.
80
 fo
r 
th
e 
co
nt
ro
l: 
t =
 −
2.
41
7,
 p
 =
 0
.0
2
Si
g. 
lo
w
er
 le
ve
ls
 o
f u
se
 o
f E
D
 (
p 
=
 0
.0
1)
, a
cu
te
 in
pa
tie
nt
 s
er
vi
ce
s 
(p
 <
 
0.
00
1)
 b
y 
th
e 
PC
 g
ro
up
 r
el
at
iv
e 
to
 c
on
tr
ol
C
am
pb
el
l 
et
 a
l.3
1
  
U
ni
te
d 
St
at
es
C
oh
or
t 
st
ud
y
≤1
 y
ea
r
44
,1
65
 
M
ed
ic
ar
e 
ho
sp
ic
e 
en
ro
le
es
20
1,
19
9 
us
ua
l 
M
ed
ic
ar
e
C
os
t
M
ea
n 
M
ed
ic
ar
e 
ex
pe
nd
itu
re
s 
in
 L
YO
L 
lo
w
er
/n
ot
 s
ig
. d
iff
er
en
t 
fo
r 
ho
sp
ic
e 
en
ro
le
es
 r
el
at
iv
e 
to
 n
on
-h
os
pi
ce
 c
on
tr
ol
s
Ex
ce
pt
 fo
r 
pa
tie
nt
s 
ag
ed
 >
85
 y
ea
rs
 w
he
re
 e
xp
en
di
tu
re
s 
w
er
e 
si
g. 
hi
gh
er
 
fo
r 
ho
sp
ic
e 
gr
ou
p:
 p
 <
 0
.0
5
N
on
-c
an
ce
r 
pa
tie
nt
s: 
m
ea
n 
M
ed
ic
ar
e 
ex
pe
nd
itu
re
s 
in
 L
YO
L 
si
g. 
hi
gh
er
 
fo
r 
ho
sp
ic
e 
en
ro
le
es
 r
el
at
iv
e 
to
 n
on
-h
os
pi
ce
 c
on
tr
ol
s: 
p 
<
 0
.0
5
C
as
se
l 
et
 a
l.4
8
  
U
ni
te
d 
St
at
es
C
oh
or
t 
st
ud
y
–
91
 p
al
lia
tiv
e 
ca
re
 (
of
 w
hi
ch
 
15
 u
se
d 
fo
r 
co
m
pa
ri
so
n 
w
ith
 c
on
tr
ol
)
20
 u
su
al
 
ho
sp
ita
l-b
as
ed
 
ca
re
C
os
t 
an
d 
ut
ili
sa
tio
n
H
os
pi
ta
l c
ha
rg
es
 fe
ll 
fr
om
 U
S$
14
68
 t
o 
U
S$
15
24
 (
20
08
 p
ri
ce
s)
 p
er
 d
ay
 
pr
io
r 
to
 P
C
 t
o 
U
S$
10
50
–U
S$
11
80
 p
er
 d
ay
 fo
llo
w
in
g 
PC
 c
on
su
lta
tio
n
C
om
pa
re
d 
w
ith
 a
 n
on
-P
C
 g
ro
up
 w
ith
 s
im
ila
r 
ag
e 
an
d 
LO
S 
in
 h
os
pi
ta
l, 
th
e 
la
tt
er
 p
at
ie
nt
s 
di
d 
no
t 
ex
pe
ri
en
ce
 t
he
 s
am
e 
de
cl
in
e 
in
 c
os
ts
 p
er
 d
ay
Fo
r 
PC
 p
at
ie
nt
s 
w
ho
 s
pe
nt
 a
t 
le
as
t 
1 
ni
gh
t 
in
 IC
U
 p
ri
or
 t
o 
PC
 
co
ns
ul
ta
tio
n,
 t
he
 P
C
 c
on
su
lta
tio
n 
ap
pe
ar
ed
 t
o 
fa
ci
lit
at
e 
a 
tr
an
sf
er
 t
o 
PC
 
su
ite
/o
th
er
 m
ed
ic
al
–s
ur
gi
ca
l r
oo
m
 by guest on July 15, 2013pmj.sagepub.comDownloaded from 
Smith et al. 9
St
ud
y 
C
ou
nt
ry
St
ud
y 
ty
pe
Pr
og
no
si
s
N
o.
 o
f p
at
ie
nt
s
C
os
t/
ut
ili
sa
tio
n
K
ey
 r
es
ul
ts
 
In
te
rv
en
tio
n
C
on
tr
ol
C
ie
m
in
s 
et
 a
l.3
0
   
U
ni
te
d 
St
at
es
C
oh
or
t
–
28
2 
pa
lli
at
iv
e 
ca
re
 (
27
 u
se
d 
fo
r 
co
m
pa
ri
so
n 
w
ith
 c
on
tr
ol
)
12
8 
us
ua
l c
ar
e
C
os
t 
an
d 
ut
ili
sa
tio
n
M
ea
n 
da
ily
 c
os
ts
 fe
ll 
by
 3
3%
 fo
llo
w
in
g 
PC
 c
on
su
lta
tio
n 
(p
 <
 0
.0
1)
M
ea
n 
da
ily
 c
os
ts
 fo
r 
pa
tie
nt
s 
fo
llo
w
in
g 
PC
 c
on
su
lta
tio
n 
w
er
e 
14
.5
%
 
lo
w
er
 t
ha
n 
m
at
ch
ed
 u
su
al
 c
ar
e 
co
ho
rt
 (
p 
<
 0
.0
1)
M
ea
n 
to
ta
l c
os
ts
 p
er
 a
dm
is
si
on
 w
er
e 
19
.2
%
 lo
w
er
 fo
r 
PC
 g
ro
up
 
co
m
pa
re
d 
w
ith
 n
on
-P
C
 g
ro
up
 (
p 
<
 0
.0
01
)
N
o 
si
g. 
di
ffe
re
nc
e 
in
 A
LO
S 
be
tw
ee
n 
PC
 a
nd
 n
on
-P
C
 g
ro
up
s
C
os
ta
nt
in
i 
et
 a
l.5
8
It
al
y
C
oh
or
t
≤6
 m
on
th
s
18
9 
pa
lli
at
iv
e 
ho
m
e-
ca
re
 
te
am
37
8 
us
ua
l c
ar
e
U
til
is
at
io
n
T
he
 p
er
ce
nt
ag
e 
of
 d
ay
s 
sp
en
t 
in
 h
os
pi
ta
l w
as
 s
ig
. l
ow
er
 fo
r 
pa
tie
nt
s 
re
ce
iv
in
g 
ca
re
 fr
om
 P
al
lia
tiv
e 
C
ar
e 
H
om
e 
Te
am
 (
19
%
; 9
5%
 C
I =
 1
5–
23
) 
co
m
pa
re
d 
w
ith
 u
su
al
 c
ar
e 
gr
ou
p 
(3
0.
3%
; 9
5%
 C
I =
 2
6–
34
)
C
ow
an
39
 
U
ni
te
d 
St
at
es
C
oh
or
t 
st
ud
y
–
16
4 
ho
sp
ita
l 
in
pa
tie
nt
 
pa
lli
at
iv
e 
ca
re
15
2 
us
ua
l 
ho
sp
ita
l-b
as
ed
 
ca
re
C
os
t 
an
d 
ut
ili
sa
tio
n
M
ea
n 
da
ily
 c
ha
rg
es
 fo
r 
PC
 p
at
ie
nt
s 
si
g. 
lo
w
er
 t
ha
n 
no
n-
PC
 g
ro
up
: p
 =
 
0.
00
6
M
ea
n 
to
ta
l c
ha
rg
es
 p
er
 P
C
 p
at
ie
nt
 h
ig
he
r 
th
an
 fo
r 
no
n-
PC
 g
ro
up
 
(lo
ng
er
 L
O
S 
fo
r 
PC
 g
ro
up
)
D
av
is
 
et
 a
l.5
6
  
U
ni
te
d 
St
at
es
O
th
er
–
–
–
C
os
t 
an
d 
ut
ili
sa
tio
n
A
ve
ra
ge
 t
ot
al
 c
ha
rg
es
 in
 P
C
 u
ni
t 
9%
 h
ig
he
r 
th
an
 n
at
io
na
l a
ve
ra
ge
 c
ha
rg
e
La
bo
ra
to
ry
 a
nd
 p
ha
rm
ac
y 
ch
ar
ge
s 
33
%
 lo
w
er
 in
 P
C
 u
ni
t 
re
la
tiv
e 
to
 
na
tio
na
l a
ve
ra
ge
Lo
ng
er
 L
O
S 
in
 P
C
 u
ni
t 
re
la
tiv
e 
to
 n
at
io
na
l a
ve
ra
ge
 (
8.
7 
vs
 7
.1
 d
ay
s)
D
ou
gl
as
 
et
 a
l.5
9
 
U
ni
te
d 
K
in
gd
om
C
oh
or
t
–
10
1 
pa
lli
at
iv
e 
da
y 
ca
re
44
 u
su
al
 c
ar
e
U
til
is
at
io
n
In
di
ca
tiv
e 
pa
tt
er
ns
: p
al
lia
tiv
e 
da
y 
ca
re
 s
ub
st
itu
te
s 
fo
r 
co
m
m
un
ity
 c
ar
e 
fo
r 
pa
tie
nt
s 
w
ho
 li
ve
 >
10
0 
da
ys
 a
ft
er
 a
tt
en
da
nc
e
In
di
ca
tiv
e 
pa
tt
er
ns
: p
at
ie
nt
s 
at
te
nd
in
g 
pa
lli
at
iv
e 
da
y 
ca
re
 fo
r 
>
10
0 
da
ys
 
ha
ve
 fe
w
er
 h
om
e-
ca
re
 in
te
rv
en
tio
ns
, m
or
e 
ac
ce
ss
 t
o 
sp
ec
ia
lis
t 
do
ct
or
s 
re
la
tiv
e 
to
 c
on
tr
ol
 g
ro
up
Em
an
ue
l 
et
 a
l.4
5
 
U
ni
te
d 
St
at
es
C
oh
or
t 
st
ud
y
≤1
 y
ea
r
37
54
 h
os
pi
ce
 
ca
re
 –
 
M
as
sa
ch
us
et
ts
; 
28
60
 h
os
pi
ce
 
ca
re
 –
 
C
al
ifo
rn
ia
30
,3
77
 n
o 
ho
sp
ic
e 
ca
re
 –
 
M
as
sa
ch
us
et
ts
; 
16
,2
04
 n
o 
ho
sp
ic
e 
ca
re
 
– 
C
al
ifo
rn
ia
C
os
t
M
ed
ic
ar
e 
ex
pe
nd
itu
re
s 
ov
er
 t
he
 L
YO
L 
fo
r 
ca
nc
er
 p
at
ie
nt
s 
13
%
‒2
0%
 
lo
w
er
 fo
r 
ho
sp
ic
e 
re
la
tiv
e 
to
 n
on
-h
os
pi
ce
 p
at
ie
nt
s
Pa
tie
nt
s 
w
ith
 o
th
er
 d
is
ea
se
s 
w
ho
 u
se
d 
a 
ho
sp
ic
e 
te
nd
ed
 t
o 
ha
ve
 h
ig
he
r 
ex
pe
nd
itu
re
s
En
ge
lh
ar
dt
 
et
 a
l.1
6
U
ni
te
d 
St
at
es
R
an
do
m
is
ed
 
co
nt
ro
lle
d 
tr
ia
l
–
93
 p
ar
tic
ip
an
ts
 
in
 a
dv
an
ce
d 
ill
ne
ss
 c
ar
e 
co
or
di
na
tio
n 
an
d 
su
pp
or
t 
pr
og
ra
m
m
e 
(c
os
t 
an
al
ys
is
)
76
 u
su
al
 c
ar
e 
(c
os
t 
an
al
ys
is
)
C
os
t
To
ta
l i
np
at
ie
nt
, o
ut
pa
tie
nt
 a
nd
 o
th
er
 c
os
ts
 w
er
e 
no
t 
si
g. 
di
ffe
re
nt
 
fo
r 
pa
tie
nt
s 
re
ce
iv
in
g 
ad
va
nc
ed
 il
ln
es
s 
co
or
di
na
te
d 
ca
re
 p
ro
gr
am
m
e 
(U
S$
12
,1
23
) 
co
m
pa
re
d 
w
ith
 u
su
al
 c
ar
e 
(U
S$
16
,2
95
) 
at
 6
 m
on
th
s 
po
st
 
en
ro
lm
en
t, 
ye
ar
 n
ot
 s
ta
te
d
En
gu
id
an
os
 
et
 a
l.2
3
U
ni
te
d 
St
at
es
C
oh
or
t 
st
ud
y
≤1
 y
ea
r
15
9 
ho
m
e-
ba
se
d 
pa
lli
at
iv
e 
ca
re
13
9 
us
ua
l c
ar
e
C
os
t
C
an
ce
r 
pa
tie
nt
s 
en
ro
lle
d 
in
 P
C
 g
ro
up
 s
pe
nt
 U
S$
59
36
 (
19
99
 p
ri
ce
s)
 le
ss
 
on
 a
ve
ra
ge
 c
om
pa
re
d 
to
 u
su
al
 c
ar
e 
(p
 =
 0
.0
01
) 
ov
er
 L
YO
L
Ta
bl
e 
2.
 (
C
on
tin
ue
d)
(C
on
tin
ue
d)
 by guest on July 15, 2013pmj.sagepub.comDownloaded from 
10 Palliative Medicine 0(0)
St
ud
y 
C
ou
nt
ry
St
ud
y 
ty
pe
Pr
og
no
si
s
N
o.
 o
f p
at
ie
nt
s
C
os
t/
ut
ili
sa
tio
n
K
ey
 r
es
ul
ts
 
In
te
rv
en
tio
n
C
on
tr
ol
Fa
ss
be
nd
er
 
et
 a
l.4
6  
 
C
an
ad
a
C
oh
or
t 
st
ud
y
≤1
 y
ea
r
16
,2
82
 p
at
ie
nt
s 
w
ho
 d
ie
d 
of
 
ca
nc
er
 1
99
3–
20
00
C
os
t 
an
d 
ut
ili
sa
tio
n
To
ta
l c
os
ts
 p
er
 p
at
ie
nt
 o
ve
r 
LY
O
L 
lo
w
er
 in
 1
99
9/
20
00
 r
el
at
iv
e 
to
 
19
93
/1
99
4
R
ef
er
ra
ls
 t
o 
an
y 
ty
pe
 o
f P
C
 s
er
vi
ce
 in
cr
ea
se
d 
ov
er
 t
im
e
Pr
op
or
tio
n 
of
 in
di
vi
du
al
s 
ad
m
itt
ed
 t
o 
a 
ho
sp
ita
l d
ec
lin
ed
 o
ve
r 
th
e 
pe
ri
od
 fr
om
 9
5%
 t
o 
83
%
 
A
LO
S 
de
cr
ea
se
d 
at
 fi
rs
t 
an
d 
th
en
 in
cr
ea
se
d 
af
te
r 
19
96
/1
99
7
G
ad
e 
et
 a
l.1
7  
  
U
ni
te
d 
St
at
es
R
an
do
m
is
ed
 
co
nt
ro
lle
d 
tr
ia
l
–
27
5 
ho
sp
ita
l-
ba
se
d 
pa
lli
at
iv
e 
ca
re
23
7 
us
ua
l 
ho
sp
ita
l-b
as
ed
 
ca
re
C
os
t 
an
d 
ut
ili
sa
tio
n
To
ta
l m
ea
n 
he
al
th
 c
os
ts
 p
er
 P
C
 p
at
ie
nt
 s
ig
. l
ow
er
 r
el
at
iv
e 
to
 c
on
tr
ol
: 
U
S$
14
,4
86
 v
er
su
s 
U
S$
21
,2
52
, p
 =
 0
.0
01
, y
ea
r 
no
t 
st
at
ed
N
o 
si
g. 
di
ffe
re
nc
es
 b
et
w
ee
n 
th
e 
PC
 a
nd
 c
on
tr
ol
 in
 L
O
S
N
o 
di
ffe
re
nc
e 
be
tw
ee
n 
th
e 
gr
ou
ps
 in
 t
he
 n
um
be
r 
of
 h
os
pi
ta
l 
re
ad
m
is
si
on
s
PC
 g
ro
up
 h
ad
 s
ig
. f
ew
er
 IC
U
 s
ta
ys
 o
n 
re
ad
m
is
si
on
 r
el
at
iv
e 
to
 c
on
tr
ol
: 
12
 v
er
su
s 
21
, p
 =
 0
.0
4
G
om
ez
-
Ba
tis
te
 
et
 a
l.3
8  
 
Sp
ai
n
C
oh
or
t 
st
ud
y
≤6
 w
ee
ks
10
0 
pa
tie
nt
s 
in
 
20
01
10
0 
pa
tie
nt
s 
in
 1
99
2
C
os
t 
an
d 
ut
ili
sa
tio
n
To
ta
l c
os
t 
pe
r 
PC
 p
at
ie
nt
 in
 2
00
1 
ov
er
 t
he
 la
st
 6
 w
ee
ks
 o
f l
ife
 €
19
63
 
co
m
pa
re
d 
w
ith
 €
50
68
 in
 1
99
2
Si
g. 
fe
w
er
 h
os
pi
ta
lis
at
io
ns
 in
 2
00
1 
re
la
tiv
e 
to
 t
he
 h
is
to
ri
ca
l p
er
io
d 
w
he
n 
PC
 s
er
vi
ce
s 
w
er
e 
in
 t
he
ir
 in
fa
nc
y: 
57
.8
%
 v
s 
72
%
, p
 <
 0
.0
01
M
ea
n 
ho
sp
ita
l s
ta
y 
pe
r 
pa
tie
nt
 o
ve
r 
th
e 
la
st
 6
 w
ee
ks
 o
f l
ife
 s
ig
. l
ow
er
 fo
r 
PC
 p
at
ie
nt
s 
in
 2
00
1 
re
la
tiv
e 
to
 1
99
2:
 1
9.
9 
da
ys
 v
s 
25
.5
 d
ay
s, 
p 
=
 0
.0
02
G
oz
al
o 
et
 a
l.3
2
   
U
ni
te
d 
St
at
es
C
oh
or
t 
st
ud
y
≤1
 m
on
th
13
08
 M
ed
ic
ar
e 
ho
sp
ic
e 
en
ro
le
es
44
66
 u
su
al
 
M
ed
ic
ar
e
C
os
t
H
os
pi
ce
 e
nr
ol
m
en
t 
si
g. 
as
so
ci
at
ed
 w
ith
 lo
w
er
 M
ed
ic
ar
e 
an
d 
M
ed
ic
ai
d 
ex
pe
nd
itu
re
 in
 la
st
 m
on
th
 o
f l
ife
 fo
r 
sh
or
t-
st
ay
 n
ur
si
ng
 h
om
e,
 n
on
-
ca
nc
er
 p
at
ie
nt
s 
(p
 <
 0
.0
01
)
Sh
or
t-
st
ay
 n
ur
si
ng
 h
om
e 
ca
nc
er
 p
at
ie
nt
s: 
ho
sp
ic
e 
en
ro
lm
en
t 
ha
d 
no
n-
si
g. 
do
w
nw
ar
d 
ef
fe
ct
 o
n 
go
ve
rn
m
en
t 
ex
pe
nd
itu
re
Lo
ng
-s
ta
y 
nu
rs
in
g 
ho
m
e,
 n
on
-c
an
ce
r 
ho
sp
ic
e 
pa
tie
nt
s: 
hi
gh
er
 
ex
pe
nd
itu
re
 r
el
at
iv
e 
to
 n
on
-h
os
pi
ce
 r
es
id
en
ts
 (
no
t 
si
g. 
fo
r 
pa
tie
nt
s 
w
ith
 
de
m
en
tia
)
Lo
ng
-s
ta
y 
nu
rs
in
g 
ho
m
e 
ca
nc
er
 h
os
pi
ce
 r
es
id
en
ts
: l
ow
er
 e
xp
en
di
tu
re
 
re
la
tiv
e 
to
 n
on
-h
os
pi
ce
 r
es
id
en
ts
 (
no
t 
si
g.
)
H
an
so
n 
et
 a
l.4
2  
 
U
ni
te
d 
St
at
es
C
oh
or
t 
st
ud
y
–
10
4 
ho
sp
ita
l-
ba
se
d 
pa
lli
at
iv
e 
ca
re
18
13
 u
su
al
 
ho
sp
ita
l-b
as
ed
 
ca
re
C
os
t 
an
d 
ut
ili
sa
tio
n
N
o 
si
g. 
di
ffe
re
nc
es
 in
 t
ot
al
 v
ar
ia
bl
e 
co
st
s 
be
tw
ee
n 
PC
 p
at
ie
nt
s 
an
d 
co
nt
ro
ls
 o
ve
r 
en
tir
e 
ho
sp
ita
l a
dm
is
si
on
 (
p 
=
 0
.7
8)
A
ve
ra
ge
 d
ai
ly
 v
ar
ia
bl
e 
co
st
s 
si
g. 
lo
w
er
 fo
r 
PC
 r
el
at
iv
e 
to
 c
on
tr
ol
 c
as
es
: 
U
S$
89
7 
vs
 U
S$
10
04
, p
 =
 0
.0
3,
 2
00
4 
pr
ic
es
N
o 
si
g. 
di
ffe
re
nc
e 
be
tw
ee
n 
PC
 a
nd
 c
on
tr
ol
 g
ro
up
s 
in
 A
LO
S
H
ig
gi
ns
on
 
et
 a
l.1
4
U
ni
te
d 
K
in
gd
om
R
an
do
m
is
ed
 
co
nt
ro
lle
d 
tr
ia
l
–
25
 fa
st
 t
ra
ck
 
pa
lli
at
iv
e 
ca
re
21
 la
te
r 
pa
lli
at
iv
e 
ca
re
C
os
t 
an
d 
ut
ili
sa
tio
n
To
ta
l c
os
ts
 o
f c
ar
e 
£1
78
9 
(2
00
5 
pr
ic
es
) 
lo
w
er
 fo
r 
PC
 g
ro
up
 o
ve
r 
12
-
w
ee
k 
pe
ri
od
: b
oo
ts
tr
ap
pe
d 
95
%
 C
I =
 −
£5
22
4 
to
 £
19
02
Ta
bl
e 
2.
 (
C
on
tin
ue
d)
 by guest on July 15, 2013pmj.sagepub.comDownloaded from 
Smith et al. 11
St
ud
y 
C
ou
nt
ry
St
ud
y 
ty
pe
Pr
og
no
si
s
N
o.
 o
f p
at
ie
nt
s
C
os
t/
ut
ili
sa
tio
n
K
ey
 r
es
ul
ts
 
In
te
rv
en
tio
n
C
on
tr
ol
   
Ex
cl
ud
in
g 
ac
ut
e 
in
pa
tie
nt
 a
nd
 in
fo
rm
al
 c
ar
e,
 m
ea
n 
se
rv
ic
e 
co
st
s 
£1
19
5 
lo
w
er
 fo
r 
PC
 g
ro
up
: b
oo
ts
tr
ap
pe
d 
95
%
 C
I =
 −
£2
91
6 
to
 £
17
8
C
on
tr
ol
 g
ro
up
 m
or
e 
lik
el
y 
to
 b
e 
in
 c
on
ta
ct
 w
ith
 G
Ps
, r
ec
ei
ve
 h
el
p 
fr
om
 
fa
m
ily
/fr
ie
nd
s, 
ad
m
itt
ed
 o
r 
se
en
 in
 h
os
pi
ta
l r
el
at
iv
e 
to
 P
C
 g
ro
up
C
os
t-
ef
fe
ct
iv
en
es
s: 
po
in
t 
es
tim
at
es
 in
di
ca
te
 t
ha
t 
th
e 
in
te
rv
en
tio
n 
is
 
co
st
-s
av
in
g 
w
ith
 e
qu
iv
al
en
t 
ou
tc
om
es
 o
n 
th
e 
PO
S-
8 
sc
al
e 
an
d 
im
pr
ov
ed
 
ou
tc
om
es
 o
n 
th
e 
Z
BI
Le
w
in
 
et
 a
l.3
5
   
U
ni
te
d 
St
at
es
C
oh
or
t
≤2
 m
on
th
17
 h
os
pi
ce
 
ca
re
67
 u
su
al
 c
ar
e
C
os
t 
an
d 
ut
ili
sa
tio
n
M
ea
n 
to
ta
l c
os
t 
pe
r 
ho
sp
ic
e 
pa
tie
nt
 o
ve
r 
la
st
 6
0 
da
ys
 o
f l
ife
 s
ig
. l
ow
er
 
fo
r 
ho
sp
ic
e 
gr
ou
p 
(U
S$
15
,1
64
) 
co
m
pa
re
d 
w
ith
 n
on
-h
os
pi
ce
 g
ro
up
 
(U
S$
59
,3
19
, p
 =
 0
.0
00
1)
, y
ea
r 
no
t 
st
at
ed
M
ea
n 
to
ta
l c
os
t 
pe
r 
da
y 
U
S$
33
3 
in
 h
os
pi
ce
 g
ro
up
 c
om
pa
re
d 
w
ith
 
U
S$
96
9 
fo
r 
no
n-
ho
sp
ic
e 
gr
ou
p 
(p
 =
 0
.0
01
1)
A
LO
S 
in
 h
os
pi
ta
l o
ve
r 
la
st
 6
0 
da
ys
 o
f l
ife
 s
ig
. l
ow
er
 fo
r 
ho
sp
ic
e 
gr
ou
p 
(3
.6
 d
ay
s)
 t
ha
n 
fo
r 
no
n-
ho
sp
ic
e 
gr
ou
p 
(1
1.
2 
da
ys
, p
 =
 0
.0
05
)
N
o 
si
g. 
di
ffe
re
nc
es
 in
 o
ut
pa
tie
nt
 v
is
its
 (
p 
=
 0
.5
13
)
Lo
22
 
Ta
iw
an
C
oh
or
t 
st
ud
y
≤1
 w
ee
k
91
2 
ho
sp
ita
l-
ba
se
d 
ho
sp
ic
e;
 
35
3 
ho
m
e-
ca
re
 
ho
sp
ic
e
25
,5
44
 
co
nv
en
tio
na
l 
ca
re
C
os
t
H
os
pi
ce
 h
as
 a
 n
eg
at
iv
e 
im
pa
ct
 o
n 
to
ta
l e
xp
en
di
tu
re
 in
 t
he
 la
st
 w
ee
k 
of
 
lif
e 
re
la
tiv
e 
to
 c
on
ve
nt
io
na
l c
ar
e 
(p
 <
 0
.0
1)
H
om
e-
ba
se
d 
ho
sp
ic
e 
ex
pe
nd
itu
re
s 
no
t 
si
g. 
di
ffe
re
nt
 fr
om
 h
os
pi
ta
l-b
as
ed
 
ex
pe
nd
itu
re
s
M
ic
ci
ne
si
 
et
 a
l.3
3
   
It
al
y
C
oh
or
t 
st
ud
y
≤3
 m
on
th
s
29
9 
ho
m
e-
ba
se
d 
pa
lli
at
iv
e 
ca
re
25
64
 n
o 
ho
m
e-
ba
se
d 
pa
lli
at
iv
e 
ca
re
C
os
t 
an
d 
ut
ili
sa
tio
n
A
ve
ra
ge
 a
cu
te
 in
pa
tie
nt
 c
os
ts
 in
 la
st
 3
 m
on
th
s 
of
 li
fe
 €
23
88
 (
€
ye
ar
 n
ot
 
st
at
ed
) 
fo
r 
PC
 g
ro
up
 c
om
pa
re
d 
w
ith
 €
33
36
 fo
r 
co
nt
ro
l (
p 
<
 0
.0
01
)
N
o 
si
g. 
di
ffe
re
nc
es
 in
 t
he
 a
ve
ra
ge
 d
ay
 h
os
pi
ta
l c
os
ts
 a
cr
os
s 
th
e 
tw
o 
gr
ou
ps
 (
p 
=
 0
.9
34
)
PC
 a
ss
oc
ia
te
d 
w
ith
 r
ed
uc
tio
n 
in
 r
el
at
iv
e 
ri
sk
 o
f h
av
in
g 
in
pa
tie
nt
 
ad
m
is
si
on
 d
ur
in
g 
th
e 
la
st
 3
 m
on
th
s 
of
 li
fe
: r
el
at
iv
e 
ri
sk
 0
.7
5,
 9
5%
 C
I =
 
0.
66
–0
.8
6
PC
 a
ss
oc
ia
te
d 
w
ith
 r
ed
uc
tio
n 
in
 r
el
at
iv
e 
ri
sk
 o
f p
ro
po
rt
io
n 
of
 d
ay
s 
sp
en
t 
in
 h
os
pi
ta
l: 
re
la
tiv
e 
ri
sk
 0
.5
1,
 9
5%
 C
I =
 0
.4
8–
0.
53
M
ill
er
 
et
 a
l.4
0,
b
 
U
ni
te
d 
St
at
es
C
oh
or
t 
st
ud
y
–
13
08
 n
ur
si
ng
 
ho
m
e 
ho
sp
ic
e
44
66
 n
ur
si
ng
 
ho
m
e 
no
n-
ho
sp
ic
e
C
os
t 
an
d 
ut
ili
sa
tio
n
M
ea
n 
to
ta
l M
ed
ic
ar
e 
an
d 
M
ed
ic
ai
d 
ex
pe
nd
itu
re
s 
in
 la
st
 m
on
th
 o
f l
ife
 s
ig
. 
lo
w
er
 fo
r 
ho
sp
ic
e 
re
la
tiv
e 
to
 n
on
-h
os
pi
ce
 r
es
id
en
ts
 (
p 
<
 0
.0
01
). 
Si
m
ila
r 
pa
tt
er
n 
ob
se
rv
ed
 fo
r 
sh
or
t-
st
ay
 n
ur
si
ng
 h
om
e 
re
si
de
nt
s. 
Lo
ng
-s
ta
y 
nu
rs
in
g 
ho
m
e 
re
si
de
nt
s: 
no
 s
ig
. d
iff
er
en
ce
s 
fo
un
d
D
iff
er
en
t 
pa
tt
er
ns
 o
bs
er
ve
d 
fo
r 
m
ea
n 
to
ta
l g
ov
er
nm
en
t 
ex
pe
nd
itu
re
s 
in
 la
st
 6
 m
on
th
s 
of
 li
fe
: s
ig
. h
ig
he
r 
fo
r 
ho
sp
ic
e 
vs
 n
on
-h
os
pi
ce
 r
es
id
en
ts
 
(p
 <
 0
.0
1)
 b
ut
 w
ith
 d
iff
er
en
ce
s 
ac
co
rd
in
g 
to
 n
ur
si
ng
 h
om
e 
LO
S. 
Fo
r 
sh
or
t-
st
ay
 n
ur
si
ng
 h
om
e 
re
si
de
nt
s, 
ex
pe
nd
itu
re
s 
si
g. 
lo
w
er
 fo
r 
ho
sp
ic
e 
us
er
s 
(p
 <
 0
.0
1)
, w
hi
le
 o
pp
os
ite
 w
as
 fo
un
d 
fo
r 
lo
ng
-s
ta
y 
nu
rs
in
g 
ho
m
e 
re
si
de
nt
s 
(p
 <
 0
.0
1)
Ta
bl
e 
2.
 (
C
on
tin
ue
d)
(C
on
tin
ue
d)
 by guest on July 15, 2013pmj.sagepub.comDownloaded from 
12 Palliative Medicine 0(0)
St
ud
y 
C
ou
nt
ry
St
ud
y 
ty
pe
Pr
og
no
si
s
N
o.
 o
f p
at
ie
nt
s
C
os
t/
ut
ili
sa
tio
n
K
ey
 r
es
ul
ts
 
In
te
rv
en
tio
n
C
on
tr
ol
M
or
ri
so
n 
et
 a
l.2
7
 
U
ni
te
d 
St
at
es
C
oh
or
t 
st
ud
y
–
26
30
 h
os
pi
ta
l-
ba
se
d 
pa
lli
at
iv
e 
ca
re
18
,4
27
 u
su
al
 
ho
sp
ita
l-b
as
ed
 
ca
re
C
os
t
D
ir
ec
t 
co
st
s 
fo
r 
PC
 g
ro
up
 o
n 
av
er
ag
e 
U
S$
16
96
 (
20
04
 p
ri
ce
s)
 lo
w
er
 p
er
 
ad
m
is
si
on
 r
el
at
iv
e 
to
 c
on
tr
ol
 g
ro
up
 (
p 
=
 0
.0
04
, o
r 
U
S$
17
4 
lo
w
er
 p
er
 
da
y, 
p 
<
 0
.0
01
)
Fo
r 
de
ce
de
nt
s, 
PC
 c
on
su
lta
tio
n 
as
so
ci
at
ed
 w
ith
 m
ea
n 
sa
vi
ng
s 
of
 
U
S$
49
08
 in
 d
ir
ec
t 
co
st
s 
pe
r 
ad
m
is
si
on
 r
el
at
iv
e 
to
 c
on
tr
ol
 g
ro
up
 (
p 
=
 
0.
00
3,
 o
r 
sa
vi
ng
s 
of
 U
S$
37
4 
pe
r 
da
y, 
p 
<
 0
.0
01
)
M
or
ri
so
n,
 
D
ie
tr
ic
h3
7
  
U
ni
te
d 
St
at
es
C
oh
or
t 
st
ud
y
–
29
0 
ho
sp
ita
l-
ba
se
d 
pa
lli
at
iv
e 
ca
re
 
(d
is
ch
ar
ge
d 
al
iv
e)
; 1
85
 
ho
sp
ita
l-b
as
ed
 
pa
lli
at
iv
e 
ca
re
 
(d
ie
d)
14
27
 u
su
al
 
ho
sp
ita
l-
ba
se
d 
ca
re
 
(d
is
ch
ar
ge
d 
al
iv
e)
; 1
49
 
us
ua
l h
os
pi
ta
l-
ba
se
d 
ca
re
 
(d
ie
d)
C
os
t 
an
d 
ut
ili
sa
tio
n
PC
 p
at
ie
nt
s 
di
sc
ha
rg
ed
 a
liv
e 
ha
d 
ad
ju
st
ed
 a
ve
ra
ge
 t
ot
al
 M
ed
ic
ai
d 
ex
pe
nd
itu
re
s 
of
 U
S$
32
,6
43
 (
20
07
 p
ri
ce
s)
 c
om
pa
re
d 
w
ith
 U
S$
36
,7
41
 
fo
r 
co
nt
ro
l g
ro
up
 (
p 
<
 0
.0
5)
Fo
r 
av
er
ag
e 
to
ta
l d
ai
ly
 c
os
ts
, P
C
 c
os
ts
 U
S$
49
0 
lo
w
er
 p
er
 d
ay
 o
ve
r 
en
tir
e 
ad
m
is
si
on
 r
el
at
iv
e 
to
 c
on
tr
ol
 g
ro
up
 (
p 
<
 0
.0
00
1)
N
o 
si
g. 
di
ffe
re
nc
e 
be
tw
ee
n 
th
e 
PC
 a
nd
 c
on
tr
ol
 g
ro
up
s 
in
 A
LO
S
O
’M
ah
on
y 
et
 a
l.5
2
  
 
U
ni
te
d 
St
at
es
Be
fo
re
-a
nd
-
af
te
r 
st
ud
y
–
77
 h
os
pi
ta
l-
ba
se
d 
pa
lli
at
iv
e 
ca
re
77
 p
re
-
in
te
rv
en
tio
n 
us
ua
l c
ar
e
C
os
t 
an
d 
ut
ili
sa
tio
n
Fo
cu
s 
on
 r
es
ul
ts
 fr
om
 c
om
pa
ri
so
n 
fo
r 
pa
tie
nt
s 
in
 9
0-
da
y 
pe
ri
od
 p
ri
or
 
to
 a
nd
 p
os
t 
PC
 in
te
rv
en
tio
n:
Si
g. 
re
du
ct
io
ns
 in
 c
ha
rg
es
 fo
r 
an
ci
lla
ry
 t
es
ts
 a
nd
 v
en
til
at
or
-r
el
at
ed
 
ch
ar
ge
s 
fo
r 
PC
 p
at
ie
nt
s 
(p
 <
 0
.0
00
1)
N
o 
si
g. 
re
du
ct
io
ns
 in
 u
til
is
at
io
n 
of
 E
D
 fo
llo
w
in
g 
PC
 c
on
su
lta
tio
n 
(2
0.
8%
–9
.1
%
, p
 =
 0
.4
3)
 o
r 
in
 h
os
pi
ta
lis
at
io
n 
ra
te
s 
(4
2.
9%
–3
5.
1%
, p
 =
 
0.
06
)
M
ed
ia
n 
LO
S 
fo
r 
ho
sp
ic
e 
pa
tie
nt
s 
si
g. 
re
du
ce
d 
(p
 <
 0
.0
5)
Pa
sc
ue
t 
et
 a
l.5
5
  
C
an
ad
a
Be
fo
re
-a
nd
-
af
te
r 
st
ud
y
–
66
 h
os
pi
ce
-
ba
se
d 
pa
ed
ia
tr
ic
 
re
sp
ite
 c
ar
e
–
C
os
t 
an
d 
ut
ili
sa
tio
n
M
ea
n 
m
on
th
ly
 h
os
pi
ta
l i
np
at
ie
nt
 d
ay
s 
fe
ll 
by
 2
.9
 d
ay
s 
in
 t
he
 p
er
io
d 
af
te
r 
pa
tie
nt
s’
 fi
rs
t 
re
sp
ite
 v
is
it 
(9
5%
 C
I =
 −
4.
5 
to
 −
1.
3,
 p
 =
 0
.0
01
)
M
ea
n 
m
on
th
ly
 h
os
pi
ta
l o
ut
pa
tie
nt
 d
ay
s 
fe
ll 
by
 0
.5
 (
95
%
 C
I =
 −
1.
0 
to
 
−
0.
05
, p
 =
 0
.0
29
)
M
ea
n 
de
cr
ea
se
 in
 m
on
th
ly
 c
os
t 
of
 in
pa
tie
nt
 c
ar
e 
of
 U
S$
42
52
 (
20
07
 
pr
ic
es
) 
(9
5%
 C
I =
 U
S$
95
3–
U
S$
75
51
, p
 =
 0
.1
2)
Pe
nr
od
 
et
 a
l.2
4
 
U
ni
te
d 
St
at
es
C
oh
or
t 
st
ud
y
82
 h
os
pi
ta
l-
ba
se
d 
pa
lli
at
iv
e 
ca
re
23
2 
us
ua
l 
ho
sp
ita
l-b
as
ed
 
ca
re
C
os
t 
an
d 
ut
ili
sa
tio
n
To
ta
l i
np
at
ie
nt
 d
ir
ec
t 
co
st
s 
pe
r 
da
y 
fo
r 
te
rm
in
al
 h
os
pi
ta
lis
at
io
n 
w
er
e 
U
S$
23
9 
(y
ea
r 
no
t 
st
at
ed
) 
lo
w
er
 fo
r 
PC
 r
el
at
iv
e 
to
 c
on
tr
ol
 g
ro
up
: 9
5%
 
C
I =
 U
S$
38
7–
U
S$
12
2
PC
 p
at
ie
nt
s 
si
g. 
le
ss
 li
ke
ly
 t
o 
be
 a
dm
itt
ed
 t
o 
IC
U
 d
ur
in
g 
ho
sp
ita
lis
at
io
n 
re
la
tiv
e 
to
 c
on
tr
ol
 g
ro
up
Pe
nr
od
 
et
 a
l.2
9  
 
U
ni
te
d 
St
at
es
C
oh
or
t 
st
ud
y
–
60
6 
ho
sp
ita
l-
ba
se
d 
pa
lli
at
iv
e 
ca
re
27
15
 u
su
al
 
ho
sp
ita
l-b
as
ed
 
ca
re
C
os
t 
an
d 
ut
ili
sa
tio
n
D
ai
ly
 h
os
pi
ta
l c
os
ts
 s
ig
. l
ow
er
 fo
r 
PC
 p
at
ie
nt
s 
re
la
tiv
e 
to
 c
on
tr
ol
D
ai
ly
 h
os
pi
ta
l d
ir
ec
t 
co
st
s 
U
S$
46
4 
lo
w
er
 fo
r 
PC
 g
ro
up
 r
el
at
iv
e 
to
 
co
nt
ro
l: 
95
%
 C
I =
 U
S$
51
5–
U
S$
41
3,
 y
ea
r 
no
t 
st
at
ed
PC
 p
at
ie
nt
s 
si
g. 
le
ss
 li
ke
ly
 t
o 
be
 a
dm
itt
ed
 t
o 
IC
U
 d
ur
in
g 
ho
sp
ita
lis
at
io
n 
re
la
tiv
e 
to
 c
on
tr
ol
 g
ro
up
Ta
bl
e 
2.
 (
C
on
tin
ue
d)
 by guest on July 15, 2013pmj.sagepub.comDownloaded from 
Smith et al. 13
St
ud
y 
C
ou
nt
ry
St
ud
y 
ty
pe
Pr
og
no
si
s
N
o.
 o
f p
at
ie
nt
s
C
os
t/
ut
ili
sa
tio
n
K
ey
 r
es
ul
ts
 
In
te
rv
en
tio
n
C
on
tr
ol
Py
en
so
n 
et
 a
l.4
1
 
U
ni
te
d 
St
at
es
C
oh
or
t 
st
ud
y
–
18
43
 M
ed
ic
ar
e 
ho
sp
ic
e 
en
ro
le
es
21
99
 u
su
al
 
M
ed
ic
ar
e
C
os
t
M
ea
n 
M
ed
ic
ar
e 
ex
pe
nd
itu
re
 p
er
 p
at
ie
nt
 d
ur
in
g 
te
rm
in
al
 p
ha
se
 o
f c
ar
e 
si
g. 
lo
w
er
 fo
r 
ho
sp
ic
e 
en
ro
le
es
 d
ia
gn
os
ed
 w
ith
 c
on
ge
st
iv
e 
he
ar
t 
fa
ilu
re
, 
liv
er
 c
an
ce
r 
an
d 
pa
nc
re
at
ic
 c
an
ce
r 
(p
 <
 0
.0
5)
N
ot
 s
ig
. i
n 
th
e 
ca
se
 o
f p
ro
st
at
e 
ca
nc
er
 a
nd
 s
tr
ok
e 
(s
ig
. h
ig
he
r 
fo
r 
st
ro
ke
, 
p 
<
 0
.0
5)
R
ab
ow
 
et
 a
l.2
1
  
U
ni
te
d 
St
at
es
N
on
-
ra
nd
om
is
ed
 
co
nt
ro
lle
d 
st
ud
y
–
50
 o
ut
pa
tie
nt
 
pa
lli
at
iv
e 
ca
re
40
 u
su
al
 
pr
im
ar
y 
ca
re
C
os
t 
an
d 
ut
ili
sa
tio
n
M
ea
n 
ch
ar
ge
 fo
r 
PC
 p
at
ie
nt
s 
U
S$
47
,2
11
 (
ye
ar
 n
ot
 s
ta
te
d)
 c
om
pa
re
d 
w
ith
 U
S$
43
,3
38
 fo
r 
co
nt
ro
l g
ro
up
 (
p 
=
 0
.8
)
PC
 g
ro
up
 s
ig
. f
ew
er
 v
is
its
 t
o 
pr
im
ar
y 
ca
re
 p
hy
si
ci
an
 (
p 
=
 0
.0
3)
, f
ew
er
 
ur
ge
nt
 c
ar
e 
cl
in
ic
 v
is
its
 (
p 
=
 0
.0
3)
N
o 
si
g. 
di
ffe
re
nc
es
 in
 s
pe
ci
al
ty
 c
lin
ic
 v
is
its
 (
p 
=
 0
.2
5)
, E
D
 v
is
its
 (
p 
=
 
0.
81
), 
ac
ut
e 
in
pa
tie
nt
 c
ar
e
R
ap
ha
el
 
et
 a
l.5
3
Fr
an
ce
C
as
e 
se
ri
es
–
33
 h
om
e-
ba
se
d 
pa
lli
at
iv
e 
ca
re
34
 h
om
e-
ba
se
d 
ch
em
ot
he
ra
py
; 
15
 h
om
e-
ba
se
d 
ot
he
r 
tr
ea
tm
en
t
C
os
t
A
ve
ra
ge
 c
os
t 
pe
r 
PC
 p
at
ie
nt
 a
t 
ho
sp
ita
l-a
t-
ho
m
e 
ov
er
 2
-w
ee
k 
ob
se
rv
at
io
n 
pe
ri
od
 w
as
 €
12
01
.7
 (
20
01
 €
s)
 c
om
pa
re
d 
w
ith
 e
st
im
at
ed
 
co
st
 o
f i
np
at
ie
nt
 h
os
pi
ta
l c
ar
e 
of
 €
34
89
.7
 (
p 
<
 0
.0
00
1)
Se
ow
 
et
 a
l.5
4
C
an
ad
a
C
as
e 
se
ri
es
–
–
–
U
til
is
at
io
n
Pa
tie
nt
s 
ad
m
itt
ed
 t
o 
ho
m
e 
ca
re
 e
ar
lie
r 
th
an
 4
 w
ee
ks
 b
ef
or
e 
de
at
h 
si
g. 
le
ss
 li
ke
ly
 t
o 
be
 h
os
pi
ta
lis
ed
, v
is
it 
an
 E
D
 o
r 
di
e 
in
 h
os
pi
ta
l
Sh
no
or
 
et
 a
l.2
6
Is
ra
el
C
oh
or
t 
st
ud
y
≤2
 m
on
th
s
73
 h
om
e 
ho
sp
ic
e 
ca
re
73
 u
su
al
 c
ar
e
C
os
t
C
os
t 
of
 c
ar
e 
in
 in
te
rv
en
tio
n 
gr
ou
p 
si
g. 
lo
w
er
 t
ha
n 
in
 t
he
 c
on
tr
ol
 g
ro
up
: 
p 
<
 0
.0
1
Si
m
oe
ns
 
et
 a
l.4
3
 
Be
lg
iu
m
C
oh
or
t 
st
ud
y
≤1
 m
on
th
88
 h
os
pi
ta
l-
ba
se
d 
pa
lli
at
iv
e 
ca
re
53
 u
su
al
 
ho
sp
ita
l-b
as
ed
 
ca
re
C
os
t
M
ea
n 
co
st
s 
pe
r 
pa
tie
nt
 p
er
 d
ay
 s
ig
. h
ig
he
r 
fo
r 
PC
 g
ro
up
 r
el
at
iv
e 
to
 
co
nt
ro
l g
ro
up
 (
p 
=
 0
.0
02
)
In
 a
n 
ac
ut
e 
w
ar
d,
 m
ea
n 
co
st
s 
pe
r 
pa
tie
nt
 p
er
 d
ay
 w
er
e 
si
g. 
lo
w
er
 fo
r 
PC
 
pa
tie
nt
s 
re
la
tiv
e 
to
 c
on
tr
ol
 (
p 
=
 0
.0
25
)
Sm
ith
 
et
 a
l.3
4
U
ni
te
d 
St
at
es
C
oh
or
t 
st
ud
y
–
38
 d
ie
d 
in
 
ho
sp
ita
l 
pa
lli
at
iv
e 
ca
re
 
un
it
38
 d
ie
d 
in
 
ho
sp
ita
l u
su
al
 
ca
re
C
os
t
To
ta
l h
os
pi
ta
lis
at
io
n 
co
st
s 
si
g. 
lo
w
er
 fo
r 
PC
 g
ro
up
 r
el
at
iv
e 
to
 c
on
tr
ol
 
fo
r 
te
rm
in
al
 h
os
pi
ta
lis
at
io
n:
 U
S$
25
38
 ±
 U
S$
29
18
 fo
r 
co
nt
ro
l v
er
su
s 
U
S$
10
95
 ±
 U
S$
11
53
, p
 =
 0
.0
00
9,
 2
00
0 
pr
ic
es
St
ev
en
so
n 
et
 a
l.5
0
 
U
ni
te
d 
St
at
es
C
oh
or
t 
st
ud
y
–
56
22
 h
om
e 
ho
sp
ic
e
16
65
 
in
st
itu
tio
n 
ho
sp
ic
e
U
til
is
at
io
n
In
st
itu
tio
na
l h
os
pi
ce
 u
se
rs
 s
ig
. m
or
e 
lik
el
y 
to
 r
ec
ei
ve
 p
hy
si
ci
an
 s
er
vi
ce
s 
(O
R
 =
 2
.5
5,
 9
5%
 C
I =
 1
.6
8–
3.
87
), 
pr
es
cr
ip
tio
n 
m
ed
ic
in
es
 (
O
R
 =
 1
.6
, 
95
%
 C
I =
 1
.1
6–
2.
2)
 a
nd
 o
th
er
s
A
ve
ra
ge
 le
ng
th
 o
f e
nr
ol
m
en
t 
si
g. 
sh
or
te
r 
fo
r 
in
st
itu
tio
na
l h
os
pi
ce
 u
se
rs
 
th
an
 fo
r 
ho
m
e 
ho
sp
ic
e 
us
er
s 
(p
 <
 0
.0
01
)
Ta
m
ir
 
et
 a
l.3
6
Is
ra
el
C
oh
or
t 
st
ud
y
≤1
 y
ea
r
12
0 
ho
m
e-
sp
ec
ia
lis
ed
 
pa
lli
at
iv
e 
ca
re
 
se
rv
ic
es
51
5 
ho
m
e 
no
n-
sp
ec
ia
lis
ed
 
pa
lli
at
iv
e 
ca
re
 
se
rv
ic
es
C
os
t
M
ea
n 
he
al
th
 s
er
vi
ce
s 
co
st
 p
er
 p
er
so
n 
in
 P
C
 g
ro
up
 o
ve
r 
LY
O
L 
31
%
 
lo
w
er
 t
ha
n 
in
 c
on
tr
ol
 g
ro
up
 (
p 
<
 0
.0
05
)
Ta
bl
e 
2.
 (
C
on
tin
ue
d)
(C
on
tin
ue
d )
 by guest on July 15, 2013pmj.sagepub.comDownloaded from 
14 Palliative Medicine 0(0)
St
ud
y 
C
ou
nt
ry
St
ud
y 
ty
pe
Pr
og
no
si
s
N
o.
 o
f p
at
ie
nt
s
C
os
t/
ut
ili
sa
tio
n
K
ey
 r
es
ul
ts
 
In
te
rv
en
tio
n
C
on
tr
ol
Ta
yl
or
 
et
 a
l.2
5
U
ni
te
d 
St
at
es
C
oh
or
t 
st
ud
y
≤1
 y
ea
r
18
19
 M
ed
ic
ar
e 
ho
sp
ic
e 
en
ro
le
es
36
38
 u
su
al
 
M
ed
ic
ar
e
C
os
t
H
os
pi
ce
 u
se
 r
ed
uc
ed
 M
ed
ic
ar
e 
ex
pe
nd
itu
re
s 
by
 a
n 
av
er
ag
e 
of
 U
S$
23
09
 
(2
00
3 
pr
ic
es
) 
in
 t
he
 t
im
e 
be
tw
ee
n 
in
iti
at
io
n 
of
 h
os
pi
ce
 c
ar
e 
an
d 
de
at
h 
re
la
tiv
e 
to
 t
he
 s
am
e 
pe
ri
od
 fo
r 
th
e 
m
at
ch
ed
 c
on
tr
ol
 g
ro
up
 (
p 
<
 0
.0
01
)
Ta
yl
or
15
  
U
ni
te
d 
St
at
es
C
oh
or
t 
st
ud
y
≤1
 y
ea
r
18
19
 M
ed
ic
ar
e 
ho
sp
ic
e 
en
ro
le
es
36
38
 u
su
al
 
M
ed
ic
ar
e
C
os
t
N
o 
si
g. 
di
ffe
re
nc
es
 o
bs
er
ve
d 
be
tw
ee
n 
ho
sp
ic
e 
an
d 
no
n-
ho
sp
ic
e 
pa
tie
nt
s 
in
 o
ut
-o
f-p
oc
ke
t 
ex
pe
ns
es
 o
ve
r 
st
ud
y 
pe
ri
od
Fa
m
ily
 m
em
be
rs
 o
f d
ec
ed
en
ts
 w
ho
 u
se
d 
ho
sp
ic
e 
be
fo
re
 d
ea
th
 h
ad
 s
ig
. 
hi
gh
er
 in
fo
rm
al
 c
ar
e 
co
st
s 
re
la
tiv
e 
to
 c
on
tr
ol
 g
ro
up
In
 la
st
 3
0 
da
ys
 o
f l
ife
, i
nf
or
m
al
 c
ar
e 
co
st
s 
fo
r 
ho
sp
ic
e 
gr
ou
p 
w
er
e 
U
S$
54
0 
(2
00
1 
pr
ic
es
) 
co
m
pa
re
d 
to
 U
S$
25
5 
fo
r 
co
nt
ro
l g
ro
up
 (
p 
=
 
0.
01
)
T
ib
i-L
ev
y 
et
 a
l.5
1  
Fr
an
ce
C
oh
or
t 
st
ud
y
–
60
 
re
ha
bi
lit
at
io
n 
pa
lli
at
iv
e 
ca
re
 
un
its
59
 a
cu
te
 
pa
lli
at
iv
e 
ca
re
 
un
its
C
os
t 
an
d 
ut
ili
sa
tio
n
C
os
t 
pe
r 
pa
tie
nt
 p
er
 d
ay
 s
ig
. l
ow
er
 in
 h
os
pi
ta
ls
 fo
cu
se
d 
on
 e
xt
en
de
d 
ca
re
 a
nd
 r
eh
ab
ili
ta
tio
n 
(p
 <
 0
.0
5)
N
o 
si
g. 
di
ffe
re
nc
e 
ob
se
rv
ed
 in
 A
LO
S 
in
 h
os
pi
ta
l f
or
 P
C
 p
at
ie
nt
s 
ac
ro
ss
 
th
e 
tw
o 
di
ffe
re
nt
 t
yp
es
 o
f h
os
pi
ta
l
T
za
la
 
et
 a
l.4
4,
b
  
G
re
ec
e
C
oh
or
t 
st
ud
y
–
27
 h
om
e-
ba
se
d 
pa
lli
at
iv
e 
ca
re
 fo
r 
ha
em
at
ol
og
ic
al
 
ca
nc
er
 p
at
ie
nt
s 
w
ho
 r
eq
ui
re
d 
m
on
ito
ri
ng
 a
nd
 
re
gu
la
r 
bl
oo
d 
tr
an
sf
us
io
ns
25
 h
os
pi
ta
l-
ba
se
d 
us
ua
l 
ca
re
C
os
t 
an
d 
ut
ili
sa
tio
n
A
ve
ra
ge
 c
os
t 
pe
r 
pa
tie
nt
 in
 h
om
e-
ca
re
 s
ch
em
e 
w
as
 €
95
8.
05
 (
€
ye
ar
 n
ot
 
st
at
ed
) 
co
m
pa
re
d 
to
 €
43
6.
34
 fo
r 
co
nv
en
tio
na
l h
os
pi
ta
l c
ar
e
In
cr
em
en
ta
l c
os
t 
di
ffe
re
nc
e:
 €
52
1.
69
, 9
5%
 C
I =
 €
51
5.
8–
€
52
7.
41
Si
g. 
gr
ea
te
r 
nu
m
be
r 
of
 b
lo
od
 t
es
ts
 p
er
fo
rm
ed
 u
nd
er
 h
om
e-
ca
re
 s
ch
em
e 
(p
 <
 0
.0
01
)
W
ar
d-
Sm
ith
 
et
 a
l.4
9  
 
U
ni
te
d 
St
at
es
C
oh
or
t 
st
ud
y
≤6
 m
on
th
s
9 
ho
sp
ita
l-
ba
se
d 
pa
lli
at
iv
e 
ca
re
9 
us
ua
l 
ho
sp
ita
l-b
as
ed
 
ca
re
C
os
t 
an
d 
ut
ili
sa
tio
n
To
ta
l h
os
pi
ta
l c
os
ts
 fo
r 
PC
 p
at
ie
nt
s 
ov
er
 la
st
 6
 m
on
th
s 
of
 li
fe
: 
U
S$
33
,2
83
–U
S$
78
3,
95
3,
 m
ea
n 
U
S$
23
1,
90
0 
(y
ea
r 
no
t 
st
at
ed
)
H
os
pi
ta
l c
ha
rg
es
 fo
r 
co
nt
ro
l g
ro
up
: U
S$
28
,9
70
–U
S$
80
3,
65
7,
 m
ea
n 
U
S$
22
8,
19
9
Fo
r 
ch
ild
re
n 
w
ho
 u
nd
er
w
en
t 
su
rg
er
y 
in
 t
he
 la
st
 6
 m
on
th
s 
of
 li
fe
, P
C
 
pa
tie
nt
s 
ha
d 
sa
m
e 
m
ea
n 
LO
S 
as
 c
on
tr
ol
 g
ro
up
W
hi
te
 
et
 a
l.4
7
 
U
ni
te
d 
St
at
es
C
oh
or
t 
st
ud
y
≤2
0 
da
ys
17
74
 h
os
pi
ta
l-
ba
se
d 
pa
lli
at
iv
e 
ca
re
52
0 
no
n-
PC
C
os
t
A
ve
ra
ge
 d
ir
ec
t 
co
st
 p
er
 d
ay
 in
 P
C
 u
ni
t 
lo
w
er
 r
el
at
iv
e 
to
 c
os
ts
 in
 IC
U
 
an
d 
al
l o
th
er
 u
ni
ts
 in
 t
he
 h
os
pi
ta
l
Su
bs
et
 o
f p
at
ie
nt
s 
tr
ea
te
d 
on
 a
no
th
er
 u
ni
t 
an
d 
tr
an
sf
er
re
d 
to
 P
C
 u
ni
t: 
av
er
ag
e 
di
re
ct
 c
os
ts
 d
ec
re
as
ed
 fo
r 
al
l p
at
ie
nt
s 
w
he
n 
tr
an
sf
er
re
d 
to
 P
C
 
un
it
PC
: p
al
lia
tiv
e 
ca
re
 (
no
n-
sp
ec
ifi
c 
us
e 
in
 t
hi
s 
ta
bl
e 
to
 r
ef
er
 t
o 
th
e 
in
te
rv
en
tio
n 
be
in
g 
st
ud
ie
d)
; A
LO
S: 
av
er
ag
e 
le
ng
th
 o
f s
ta
y; 
ED
: e
m
er
ge
nc
y 
de
pa
rt
m
en
t; 
LY
O
L:
 la
st
 y
ea
r 
of
 li
fe
; C
I: 
co
nf
id
en
ce
 in
te
rv
al
; L
O
S: 
le
ng
th
 o
f s
ta
y; 
IC
U
: i
nt
en
si
ve
 c
ar
e 
un
it;
 s
ig
.: 
si
gn
ifi
ca
nt
 (
re
fe
rs
 t
o 
st
at
is
tic
al
 s
ig
ni
fic
an
ce
).
a S
om
e 
of
 t
he
 s
tu
di
es
 u
nd
er
ta
ke
 a
dd
iti
on
al
 a
na
ly
si
s 
th
at
 is
 o
ut
si
de
 t
he
 fo
cu
s 
of
 t
he
 c
en
tr
al
 r
es
ea
rc
h 
qu
es
tio
n 
fo
r 
th
e 
re
vi
ew
. T
he
 r
es
ul
ts
 p
re
se
nt
ed
 a
nd
 d
is
cu
ss
ed
 in
 s
ec
tio
ns
 ‘R
es
ul
ts
 fo
r 
lit
er
at
ur
e 
re
vi
ew
 
(2
00
2–
20
11
)’ 
an
d 
‘C
on
cl
us
io
n’
 fo
cu
s 
on
ly
 o
n 
th
e 
an
al
ys
is
 r
el
ev
an
t 
to
 t
hi
s 
re
vi
ew
.
b F
oc
us
 o
n 
co
st
 r
es
ul
ts
 o
nl
y.
Ta
bl
e 
2.
 (
C
on
tin
ue
d)
 by guest on July 15, 2013pmj.sagepub.comDownloaded from 
Smith et al. 15
The papers were also categorised according to whether 
they focused on costs, utilisation or both. Most of the stud-
ies focus on costs either with or without separate analysis of 
health-care utilisation. Of the five RCTs, 3 are ‘both cost 
and utilisation studies’, 1 is ‘cost only’ and 1 is ‘utilisation 
only’. The non-randomised controlled studies are all ‘both 
cost and utilisation papers’. The cohort studies comprise 15 
‘cost’ studies, 15 ‘both cost and utilisation’ studies and 4 
‘utilisation only’ studies. The before-and-after studies and 
one other study are ‘both cost and utilisation’ papers. Of the 
two case series papers, 1 is ‘cost only’ and 1 is ‘utilisation 
only’. Just one out of the 46 studies reports cost-effective-
ness analysis,14 illustrating the scarcity of this type of anal-
ysis in the palliative care field. Almost all of the cost studies 
focus on directly observable costs. Informal care costs are 
included in two studies,14,15 and out-of-pocket costs are the 
focus of one study,15 although in some cases it is not clear 
whether out-of-pocket copayments have been included. As 
noted in other reviews,7 there is variation in the cost data 
used with some studies relying on charges, others on 
observed expenditures and the remaining on detailed bot-
tom-up estimates based on actual resource use.
In all, 31 of the papers are based on data from the United 
States and this is important when considering the generalis-
ability of the findings to other health-care systems. The 
remaining studies are based on data from Belgium (1), 
Canada (2), France (2), Greece (1), Israel (2), Italy (2), 
Spain (1), Taiwan (1) and the United Kingdom (2).
Study quality
Figure 2 gives a graphical summary of the quality score 
results. The RCTs and non-RCTs perform well for all indi-
cators with the exception of ‘reporting’ where there is some 
variation. The quality of the cohort studies (n = 34) varies 
across the indicators. Most perform well on study descrip-
tion, measurement and conclusions, but results are mixed 
for sample selection and size, reporting and analysis. The 
case studies perform well for all indicators. The quality 
score results for the remaining studies were mixed.
It is useful to discuss the findings of the papers in some 
order of priority based on the quality assessment. 
Notwithstanding the caveats in generating summary quality 
scores for papers, there is scope for combining information 
on the scores with other factors to generate broad quality 
rankings. This review assigns papers into groups based on 
a joint assessment of the total quality scores and the type of 
analysis undertaken in each study.
RCTs are typically considered to be the gold standard 
for evaluating the effects of an intervention. An appropri-
ately designed and implemented RCT allocates participants 
to the intervention and control groups using randomisation 
and concealment, which should ensure that the groups 
being compared are ‘similar in all respects other than the 
intervention’ (p. 34).9 RCTs are typically assessed for risk 
of bias along key dimensions including sequence genera-
tion, allocation concealment, blinding (of participants and 
outcome assessors), outcome data, outcome reporting and 
other sources of bias.8 Based on a brief assessment, the five 
RCTs14,16–19 perform relatively well along these dimensions 
although there is some lack of clarity in terms of blinding 
and allocation concealment. As noted, these studies per-
form well on the quality criteria compiled for this review 
and rank among papers of highest quality.
In non-RCTs, participants are allocated to the interven-
tion and control groups using methods other than randomi-
sation.9 This increases the risk of selection bias, whereby 
individuals can be deliberately selected (or self-select) to 
the intervention or control group meaning that the results of 
the trial may be influenced by systematic differences 
between the study groups in terms of participant behav-
iours/prognosis. The two non-RCTs performed well against 
the quality criteria for this review.20,21 The first of these 
studies controlled for variations in individual characteris-
tics across the groups using appropriate multivariate statis-
tical techniques.20 In the second study, although patients 
were not individually randomised to the intervention group, 
there was some randomisation at a higher level (i.e. two 
general medical practices operating alongside each other 
and a coin flip determined, which would form the interven-
tion group and form the control).21
Grouping the cohort studies according to whether multi-
variatei or univariateii analysis was undertaken, the average 
total quality score is higher for the group of multivariate 
analysis studies (0.82 versus 0.68). Subdividing the ‘uni-
variate’ group into studies that undertook formal statistical 
analysis and those that did not (e.g. no t-tests, chi-square 
tests and so on), there are differences in the average total 
quality score (0.70 versus 0.63). The variation in average 
quality among these three groups is even more distinct in 
terms of the average scores on the analytic dimension of 
quality: 0.85 for multivariate studies, 0.64 for univariate 
studies with formal statistical tests and 0.11 for studies with 
no formal statistical analysis.
Study findings on costs
In two out of six RCTs/non-RCTs that include cost data, the 
costs of the palliative care intervention were significantly 
i Multivariate analysis involves analysing the impact of a particu-
lar variable on an outcome of interest, while taking into account 
(i.e. controlling for) the effects of all other variables that may 
influence the outcome of interest (e.g. regression analysis).
ii Univariate analysis examines the association between a par-
ticular variable and an outcome of interest, without control-
ling for any other factors that may influence the outcome of 
interest. The association can be tested for statistical signifi-
cance using a range of statistical tests (e.g. t-tests, chi-square 
tests) depending on the type of variables involved (continu-
ous, categorical).
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lower than the costs for the control group.17,18 In three fur-
ther studies, the costs were lower for the palliative care 
intervention although not significantly different,14,16 or no 
report of statistical significance.20 In the remaining studies, 
costs were higher, but not significantly different, in the 
intervention group relative to the control group.21 
Throughout this review, the term ‘significant’ refers to 
statistical significance and the level of statistical signifi-
cance (i.e. p value) is indicated where available.
Four of the RCTs included data on costs. One US study 
focused on a hospital-based palliative care programme.17 
Costs were computed for all health services used within 6 
months following index hospitalisation discharge (e.g. hos-
pital outpatient, home health visits, hospital readmissions 
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Figure 2. Study quality (n = 46).
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and skilled nursing facility admissions). Univariate analy-
sis found that total mean health costs per patient for the 
palliative care intervention group were significantly lower 
than the usual care control group (US$14,486 versus 
US$21,252, p = 0.001, year not stated although data were 
collected between 2002 and 2003). Cost savings were 
largely driven by a significant difference in hospital read-
mission costs (US$6421 per palliative care patient versus 
US$13,275 per usual care patient, p = 0.009). A second US 
study focused on an in-home palliative care programme 
and observed significantly lower costs for the palliative 
care group relative to the usual care control group.18 Costs 
included acute inpatient, ambulatory, home health and pal-
liative care costs. Total costs were on average US$7552 (at 
2002 prices) lower for the in-home palliative care group 
over the study period (95% confidence interval (CI) = 
−US$12,730 to −US$2374, t = −3.63, p < 0.001), even after 
adjusting for a shorter survival period (i.e. from study 
enrolment to death) for the intervention group (196 days vs 
242 days for the control group). The average cost of care 
per day was US$95.30 for the intervention group compared 
to US$212.80 for the control group, a significant difference 
(t = −2.417, p = 0.02).
The third RCT is a UK cost-effectiveness study of a new 
palliative care service for people with multiple sclerosis. 
The study found that total costs of care, including acute 
inpatient, ambulatory, other social/community care and 
informal care costs were £1789 (2005 prices) lower for the 
palliative care intervention group over a 12-week follow-up 
period (bootstrapped 95% CI = −£5224 to £1902). 
Excluding acute inpatient and informal care, mean service 
costs were £1195 lower for the intervention group (boot-
strapped 95% CI = −£2916 to £178).14
The fourth RCT is a US-based study of an advanced ill-
ness coordinated care programme designed to improve the 
care of people with serious illness to help them cope with 
advanced illness and with making end-of-life decisions. 
The study examined inpatient, outpatient, nursing home, 
inpatient hospice and other costs (e.g. diagnostic services) 
for participants and non-participants from 6 months prior to 
enrolment in the programme to 6 months post enrolment. 
Results found that total costs of care were lower for patients 
participating in the programme (US$12,123 per patient, 
year not stated, paper published in 2006) than for non-par-
ticipants (US$16,295 per patient) at 6 months post enrol-
ment. This difference in costs was not statistically 
significant (p = 0.18).16
Two US studies undertook non-RCTs of palliative 
care.20,21 One focused on comparing an outpatient pallia-
tive medicine consultation intervention with usual pri-
mary care. Costs included physician office visits, 
emergency department visits and acute inpatient care. 
Results found that the mean charge for the palliative care 
patients over the study period was US$47,211 (year not 
stated, paper accepted for publication in 2003) compared 
with US$43,338 for the control group, and this difference 
was not statistically significant (p = 0.8).21 The second 
study focused on a home-based palliative care pro-
gramme, comparing this with standard home health ser-
vices. Costs analysed referred to staffing costs only. 
Results found that the mean cost of care for the palliative 
care group was US$6580 (1999 prices) lower than the 
mean cost for the control group, after controlling for var-
iation in the number of days receiving the service, sever-
ity of illness and having a congestive heart failure 
diagnosis (p values not reported).20
In the cohort studies that undertook multivariate analy-
sis of costs, 9 out of 11 studies found evidence of signifi-
cantly lower costs in the palliative care intervention relative 
to the control group.22–30 The remaining two studies, both 
based in the United States, identified a more complex pic-
ture when disaggregating by age, cancer and length of nurs-
ing home enrolment.31,32
Five studies analysed the impact of hospice care on 
health-care expenditure. Three of these were US studies that 
investigated the impact of hospice care on Medicare (and in 
one case Medicaid also) expenditure during the last year of 
life. One study25 used propensity score matching to control 
for variation in demographic and clinical characteristics of 
individuals across the hospice and non-hospice control 
groups. Results showed that hospice use reduced Medicare 
expenditures by an average of US$2309 (2003 prices) in the 
time period between initiation of hospice care and death 
relative to the same period for the matched control group (p 
< 0.001). The impact of hospice use on government expen-
ditures was found by the other two studies to vary according 
to age, patient diagnosis and/or nursing home status.31,32 
One study based in Taiwan22 also undertook multivariate 
regression analysis, controlling for self-selection, demo-
graphic and clinical factors, examining the impact of hospi-
tal-based and home-based hospice on health-care 
expenditures per patient in the week before death. Results 
indicate that hospice has a negative impact on total expendi-
ture in the last week of life relative to conventional care (p < 
0.01), controlling for other factors. A study in Israel focused 
on the impact of home hospice on health-care expenditures 
in the last 2 months of life relative to conventional care.26 
Multivariate regression analysis found that controlling for 
gender, age and the number of treatment items per patient, 
the cost of care in the intervention group was significantly 
lower than in the control group (p < 0.01).
Five US studies examined the impact of hospital-based 
palliative care on health-care expenditure.24,27–30 Results 
were consistent across these studies, each finding palliative 
care to be associated with significantly lower inpatient 
costs. Three of these studies used propensity score match-
ing to control for variation in demographic and clinical 
characteristics of individuals across the palliative care 
intervention and usual care groups.24,27,29 For example, in 
one study, for patients discharged alive from hospital, direct 
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costs for the palliative care group were on average US$1696 
(2004 prices) lower per admission relative to the control 
group (p = 0.004, or US$174 lower per day, p < 0.001). For 
patients who died in hospital, palliative care consultation 
was associated with mean savings of US$4908 in direct 
costs per admission relative to the control group (p = 0.003, 
or savings of US$374 per day, p < 0.001).27
One US study undertook multivariate analysis of the 
impact of a palliative care home-based programme on staff 
costs relative to usual home health care.23 Results showed 
that cancer patients enrolled in the palliative care group spent 
US$5936 (1999 prices) less on average compared to those in 
usual care (p = 0.001) over the last year of life, controlling 
for severity of illness and the number of days on service.
In the cohort studies that undertook univariate statistical 
analysis, 5 out of 13 studies found evidence of significantly 
lower costs in the palliative care intervention group com-
pared with the control group,33–37 and a sixth study found 
evidence of lower costs without reporting statistical signifi-
cance.38 Five others found some evidence for significantly 
lower costs in the palliative care intervention group, but not 
consistently so, and variations were observed over a number 
of different factors including diagnosis, nursing home length 
of stay, daily cost versus total admission cost, type of ward 
on which palliative care was provided and time period stud-
ied.39–43 One study found evidence of significantly higher 
costs in a home-care scheme relative to conventional hospi-
tal care, although these results require careful interpretation 
because of the additional number of blood tests intentionally 
provided under the home-care scheme.44 One study focus-
ing on out-of-pocket expenses found no significant differ-
ences between the intervention and control groups, while 
finding informal care costs significantly higher in the inter-
vention group,15 underlining the importance of paying more 
attention to the indirect cost in palliative care.
The five cohort studies that did not undertake formal sta-
tistical analysis observed patterns of lower expenditures 
related to palliative care45–48 or no difference in costs 
between palliative care and non-palliative-care patients.49
Three cohort studies compared palliative care costs across 
different types of palliative care.22,50,51 A study based in 
Taiwan observed no significant differences between home-
based and hospital-based hospice expenditures per patient in 
the week before death, controlling for other factors.22 One 
US study examined utilisation differences in hospice care 
between the institutional and home setting.50 Multivariate 
analysis of utilisation over a 30-day period, adjusting for 
patient characteristics and length of enrolment, found institu-
tional hospice users were significantly more likely to receive 
several types of services including physician services (odds 
ratio (OR) = 2.55, 95% CI = 1.68–3.87), prescription medi-
cines (OR = 1.6, 95% CI = 1.16–2.2) and others. Average 
length of enrolment was significantly shorter for institutional 
hospice users than for home hospice users (p < 0.001). A 
study based in France examined variations in hospital-based 
palliative care costs across different types of hospitals 
(hospitals providing medical, surgical and obstetric care ver-
sus hospitals offering extended care and rehabilitation).51 
Univariate analysis found that the cost per patient per day 
was significantly lower in the hospitals focused on extended 
care and rehabilitation (p < 0.05), driven by differences in 
personnel and medications costs.
Case studies, before-and-after, other studies
Of the five studies that investigated the impact of palliative 
care on health-care costs using alternative methods to 
including a formal comparison group, four found evidence 
of significantly lower costs related to the palliative care 
intervention.52–55 The fifth found evidence of higher charges 
for palliative care relative to a national average charge.56 
For example, one of the case studies, based in France, com-
pared the cost of hospital at home services with the esti-
mated cost of treating the same patients in a standard 
hospital setting.53 Univariate analysis found that for patients 
considered to be at the palliative care stage, the average 
cost per patient of hospital-at-home over a 2-week observa-
tion period was €1202 (2001 prices) compared with the 
estimated cost of inpatient hospital care of €3490, a signifi-
cant difference (p < 0.0001).
Study findings on health-care utilisation
In general, the impact of palliative care on resource utilisa-
tion is mixed as illustrated by one of the highest quality rank-
ing cohort studies, which focused solely on the use of services 
(i.e. no cost data57). This US study used multivariate analysis 
to compare resource use by cancer decedents who received 
hospital-based palliative care with those who received usual 
care. Results indicated that patients in the palliative care 
group who were enrolled for longer than 113 days were less 
likely than the control group to have an acute care admission 
during the last 60 days of life (OR = 0.306, 95% CI = 0.117–
0.802). The average length of stay per acute care admission 
was significantly shorter for palliative care patients relative 
to the control group (p < 0.05). Results on the total number 
of acute care days within the last 60 days of life depended on 
the length of palliative care enrolment. Palliative care patients 
who were enrolled in palliative care for less than 60 days 
were more likely to have a greater number of total acute care 
bed days relative to the control group (p < 0.05). Palliative 
care patients who were enrolled for more than 60 days were 
more likely to have a smaller number of total acute care bed 
days relative to the control group (p < 0.05).
The mixed results apply to all of the study categories 
included in the review. Of the six RCTs/non-RCTs with uti-
lisation data, three studies found evidence of lower use of 
some hospital services,17,18,20 while three found no signifi-
cant differences in others.17,19,21 Of the cohort studies that 
report specific results on health-care utilisation, the same 
mixed pattern is observed,24,28–30,33,35,37–39,42,44,46,48,49,58,59 
while detailed analysis by two studies33,57 illustrate the 
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varied impacts of palliative care on utilisation (e.g. depend-
ing on time period studied, length of enrolment).
Study findings on cost-effectiveness
Only one of the studies met the criteria for a cost-effective-
ness study.14 Patient outcomes were measured on the 
Palliative Care Outcome Scale (POS-8)iii and caregivers’ 
burden was measured using the Zarit Carer Burden Inventory 
(ZBI). There was no significant difference in the POS-8 
measure over the trial, while ZBI scores improved for the 
intervention group and worsened for the control group. The 
point estimates indicate that the intervention is cost-saving 
with equivalent outcomes on the POS-8 scale and improved 
outcomes on the ZBI. Sensitivity analysis examined uncer-
tainty around those point estimates. For the POS-8 measure, 
the cost-effectiveness plane shows the intervention group 
had lower costs and better outcomes than the control group 
33.8% of the time, and lower costs and worse outcomes 
54.9% of the time. When the cost-effectiveness analysis is 
based on the ZBI measure, the intervention group shows 
lower costs and better outcomes 47.3% of the time, and 
higher costs and better outcomes 48% of the time.
Conclusion
Overall, the review presents an up-to-date picture of the 
most recent analysis being undertaken on the cost (and 
resource use) implications of palliative care interventions 
over the period 2002–2011. The main focus of these studies 
is on direct costs, from the provider or third-party payer per-
spective, with little focus on informal care or out-of-pocket 
costs. While a small number of studies follow an RCT or 
non-RCT format, the majority of studies are described as 
cohort studies and therefore need measures to control for 
confounding factors and selection bias in the analysis. The 
overall quality of the studies is mixed, although a number of 
cohort studies do undertake multivariate regression analysis 
and include measures to control for selection bias.
The evaluation criteria, combined with information on the 
type of statistical analysis undertaken, have provided a useful 
overview of the overall quality of the papers. The absence of 
randomisation in most of the studies highlights the impor-
tance of controlling for confounding factors and selection 
bias when analysing the impact of a palliative care interven-
tion on the outcome of interest. A number of the cohort stud-
ies have undertaken multivariate regression analysis, and 
many of these have also used propensity score matching 
techniques to control for selection into the intervention and 
control groups. In general, the RCT papers, the non-RCTs 
and the cohort and case studies that undertook multivariate 
analysis are at the higher end of the quality scale.
In terms of generalisability, a couple of points should be 
considered. The models of care and reimbursement for pal-
liative care pursued across different countries can vary 
widely, which is particularly relevant here as a large pro-
portion of the 46 studies examined here are based on United 
States. In addition, while the included studies focus on both 
malignant and non-malignant conditions, it is recognised 
that conditions may follow different trajectories.
However, despite the wide variation in study type, char-
acteristic and study quality, there are consistent patterns in 
the results. Palliative care is most frequently found to be 
less costly relative to comparator groups, and in most cases, 
the difference in cost is statistically significant. It is also 
worth noting that there may be complex interactions 
between costs of care and diagnosis (e.g. cancer/non-cancer 
distinctions), age groups and other factors (e.g. length of 
nursing home enrolment in US studies) that require further 
investigation and in particular the role played by informal 
care needs to be analysed in more detail.
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